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ABSTRACT 
 
 PALMITOYLATION AND POLARITY: ASYMMETRIC PARTITIONING OF NOTCH AND 
WNT SIGNALING BY REVERSIBLE LIPID MODIFICATION IN DIVIDING CELLS 
Ewa Stypulkowski 
Eric S. Witze 
Protein palmitoylation is a reversible lipid modification that regulates protein-membrane 
interaction, activity, trafficking, and stability in a spatio-temporal manner similar to 
phosphorylation and ubiquitination.  Asymmetric cell division results in two distinctly fated 
daughter cells, by unequally partitioning proteins known as cell fate determinants. I have 
characterized a mechanism for protein palmitoylation to asymmetrically partition cell fate 
determinants, e.g. Numb and β-catenin, through the activity of the depalmitoylating enzyme 
APT1. Using point mutations, I have found specific palmitoylated residues on Numb are required 
for its asymmetric localization in dividing cells. By live-cell imaging, I have also identified a 
reciprocal interaction between APT1 and the Rho family GTPase, CDC42, which promotes 
asymmetric localization of Numb and β-catenin to the plasma membrane.  In turn, this 
mechanism restricts Notch- or Wnt-responsive transcriptional activity to one daughter cell. 
Moreover, I show that altering APT1 expression levels alters the transcriptional signatures of 
MDA-MB-231 triple receptor-negative breast cancer cells, resembling altered Notch and β-
catenin-mediated Wnt signaling. Furthermore, loss of APT1 depletes a specific subpopulation of 
tumorigenic cells. Together, this dissertation presents palmitoylation as a major mechanism of 
asymmetric cell division that maintains Notch- and Wnt-associated protein dynamics, gene 
expression, and cellular functions. 
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CHAPTER 1: INTRODUCTION  
 
1.1 Summary 
 Significant effort has gone into elucidating the molecular mechanisms regulating the 
polarized protein localization of proteins in cells and tissues during development, homeostasis, 
and disease. Lipid modification is a class of post-translational modifications that facilitates and 
stabilizes protein targeting to intracellular membrane domains. This enables the formation of 
polarized signaling domains at the membrane to propagate downstream signal transduction. 
Protein palmitoylation is a reversible lipid modification that regulates protein-protein and protein-
membrane interaction, activity, trafficking, and stability in a spatio-temporal manner similar to 
phosphorylation and ubiquitination. Despite an evolutionarily conserved requirement for 
palmitoylation on many key cellular processes, numerous technical challenges have made it 
difficult to study palmitoylation in real-time and in situ.  These obstacles include a lack of 
antibodies to palmitoylated domains and live-cell imaging probes to measure palmitoylation at 
the single cell level. In this chapter, I will discuss the evidence, technological advances, and 
emerging roles for palmitoylation on protein function and cellular processes.  
 
1.2 Overview  
 Cellular responses to intrinsic (genetic) cues or extrinsic (environmental) signaling cues 
are essential to drive polarized behaviors essential for embryonic development and tissue 
homeostasis such as axial patterning, convergent extension, wound healing, and tissue 
morphogenesis (1, 2). Within the cell, molecular mechanisms drive the polarized segregation of 
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signaling effectors to specialized plasma and endomembrane domains in response to extrinsic and 
intrinsic cues to facilitate protein-protein interactions (3, 4). Formation of these polarized 
domains, e.g. apical/basolateral, allows various parts of the cell to carry out specialized functions 
such as cell migration, invasion, and asymmetric cell division (1). Processes such as germ layer 
specification, differentiation, and proliferation require precise spatio-temporal regulation of 
various signaling pathways at distinct subcellular domains. In addition to spatial localization, the 
protein-protein interactions must be temporally regulated for proper development and tissue 
function.  Loss of polarized protein localization may promote the excessive or insufficient 
duration signaling activity, resulting in developmental disorders (including embryonic lethality), 
neurodegenerative disorders, and cancer (3, 5, 6).  
Soluble, cytosolic proteins can localize to the membrane through random diffusion; 
however, these transient interactions are insufficient to propagate a signal over time (4, 7–9). 
Polarized protein localization is widely regulated by post-translational modifications that alter the 
structure and biophysical properties of proteins to modulate activity, stability, protein-protein 
interaction, and subcellular localization, and include phosphorylation, acetylation, ubiquitination, 
methylation, and lipid modification (4, 10–12). Post-translational lipid modification increases the 
hydrophobicity of cytosolic proteins, which enables recruitment and stable association with lipid 
rafts and other membrane domains. This stable association can bring signaling effectors into close 
proximity of each other to propagate signaling cascades that, in turn, influence cell identity and 
function (6, 13–16).  
Myristoylation, prenylation, and palmitoylation are three of the most common lipid 
modifications; palmitoylation is unique in that the modification can be enzymatically reversed. 
Because of its dynamic properties, palmitoylation spatio-temporally modulates protein activity, 
stability, and transport between intracellular compartments, a key requirement of establishing cell 
 
 
3 
polarity (4, 6, 12). In this manner, palmitoylation is regarded as a regulatory switch similar to 
phosphorylation or ubiquitination (6, 16–18).   
First studied in viruses in the late 1970s, palmitoylation has since been examined in 
bacteria and eukaryotes from yeast to humans (11, 18–23). It plays a role in diverse cellular and 
developmental processes including, but not limited to, receptor kinase activity (24–33), ion 
channel function  (32, 34–41), apoptosis (29, 42–44), immunomodulation (45–50), cell junction 
assembly (51–55), cellular senescence (56–58), genomic stability (24, 59–62), neural cells 
development (63, 64), and progenitor cell maintenance (25, 55, 65–67). Palmitoylation also 
maintains the activity of signaling pathway such as Wnt (68–71), G-protein coupled receptor (9, 
11, 72, 73), epithelial growth factor receptor (26, 27, 74), and Ras  (9, 11, 75, 76). Disruption of 
palmitoylation has been linked to the pathogenesis of diseases from Huntington’s disease (77–
80), Alzheimer’s disease (44, 81–83), neuropsychiatric disorders (84–87), cancer (26, 60, 70, 71, 
88–94), and exploratory studies may implicate aberrant palmitoylation on metabolic disorders 
(35, 95–97), and musculoskeletal defects (39, 40, 98–101).  These examples highlight the diverse 
biological functions regulated by palmitoylation, although may substrates and the regulation of 
palmitoylation during these processes still remain to be determined. 
Uncovering how palmitoylation regulates protein interactions and localization within a 
cell may open new opportunities for understanding how signaling pathways are coordinated 
within an organism to ensure proper development and homeostasis, and how these pathways are 
dysregulated in disease which may advance the development of targeted therapeutic strategies.  
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1.3 Introduction to protein palmitoylation  
Palmitoylation is the covalent linkage of a 16-carbon palmitate group to a cysteine 
residue via a labile thioester bond (16, 18, 22). Unlike myristoylated or prenylated proteins, 
where the lipid group generally remains attached for the protein’s lifetime, palmitate is 
dynamically turned over.  The rate of palmitate turnover varies between substrate as some 
proteins (TEAD, SNAP25 and synaptotagmin I) remain palmitoylated for hours, while others 
(Ras, CDC42, Lck, and PSD-95) are rapidly depalmitoylated within minutes (11, 15, 102).  This 
turnover allows regulation of protein trafficking and sorting between membrane compartments 
like the Golgi, endoplasmic reticulum, and plasma membrane (4, 12, 14) (Fig. 1.1 A). 
Palmitoylation can also modulate the conformation and activity of transmembrane receptors and 
other integral membrane proteins to facilitate downstream activity by regulating the association 
between the cytosolic tail and the membrane to restrict or promote access to binding partners (4, 
6, 12, 17)
 
(Fig. 1.1 B). Hydrophobic protein pockets can be palmitoylated to restrict accessibility 
to catalytic clefts, and palmitoylation can sterically hinder amino acid residues from 
ubiquitinating enzymes to inhibit protein degradation (6, 10)
 
(Fig. 1.1 C).  These examples 
demonstrate how palmitoylation can modulate cellular responses (12–14).  
A single lipid group is generally not sufficient to maintain a stable protein-membrane 
interaction, and therefore, proteins are dual-lipid modified with palmitate and another lipid group 
(4, 9). Proteins containing a single prenyl or myristate group, such as Ras, Fyn kinase, or Gα 
subunits, briefly associate with membranes (4, 9). Adding a second lipid group increases the 
amount of time a protein resides at a membrane, thus promoting a sustained downstream signal 
cascade (4, 9, 10, 14). For example, prenylated Ras preferentially localizes to the Golgi, but the 
addition of palmitate drives its localization to plasma membrane. Regulated cycling between the 
Golgi and plasma membrane maintains appropriate Ras distribution within the cell to keep Ras 
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signaling in check (4, 9). Inhibiting depalmitoylation with small molecule agents results in 
nonspecific intracellular localization and downregulated Ras signaling (9, 75, 103). A member of 
the Src family of kinases, Lyn, is dually myristoylated and palmitoylated; this is thought to 
prevent chromosome missegregation by restricting Lyn at the plasma membrane and preventing 
nuclear translocation (24). Dual lipid modification also facilitates the cycling of neuronal synaptic 
proteins PSD-95 and GAP43 cycle between the cytosol and synaptic membranes or axonal 
outgrowths (9, 11, 14). These examples demonstrate how palmitoylation serves as a critical 
mechanism to spatio-temporally regulate protein localization to maintain signaling activity and 
protein interactions, such as ligand-receptor interactions (17). 
While the majority of palmitoylated proteins undergo enzymatically regulated cycles of 
palmitoylation and depalmitoylation, a smaller number of palmitoylated proteins are irreversibly 
modified (10). Ligands and hormones like Spitz (an EGFR-activating ligand), Hedgehog, Wnt, 
and preghrelin are irreversibly palmitoylated, which facilitates proper post-translational 
processing and secretion out of the cell (9, 10, 16).  Although a recent study identified Wnt 
ligands are depalmitoylated by Notum (104), irreversibly palmitoylated proteins are not known to 
cycle between palmitoylated and unpalmitoylated states as reversibly modified proteins do. While 
irreversible palmitoylation is critical for cell signaling, this chapter will discuss the biological 
function of the more ubiquitously studied reversible palmitoylation.  
 
1.4 Enzymatic regulation of palmitoylation-depalmitoylation cycles 
Palmitoylation is catalyzed by two classes of evolutionarily conserved enzymes: 
palmitoyltransferases and depalmitoylating enzymes (9, 10) (Fig. 1.2). The multi-pass DHHC 
transmembrane proteins make up the largest class of palmitoyltransferases. This family was first 
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isolated in yeast and is characterized by a cysteine-rich domain containing a highly conserved 
DHHC (Aspartate-Histidine-Histidine-Cysteine) zinc-finger motif (105–107). The number of 
DHHC enzymes varies with species, e.g. 7 in yeast, 23 in mammals, 24 in plants and 
invertebrates (D. melanogaster) (16, 18, 23).  As a large group, DHHCs share many functional 
redundancies and substrates. Unlike myristoylation or prenylation, which have defined substrate 
recognition sequences, palmitate can be added to any cysteine (10, 22). Because of this, a defined 
palmitoylation-recognition sequence has not yet been identified making it difficult to predict 
palmitoylated proteins based on amino acid sequence. Ankyrin-repeat domains have been 
suggested as a potential DHHC recognition sequence (15, 108, 109). Specific substrate-DHHC 
pairs have also been observed depending on tissue context, cellular compartment, or even amino 
acid sequence (15, 23, 110). Due to the abundance of palmitoylated proteins, the size of the 
DHHC famil, and ambiguity in substrate-DHHC specificity have made it challenging to 
characterize bona-fide substrate-enzyme pairs in vivo (14, 17).  
 Palmitate transfer from enzyme to substrate is a two-step process, which involves 
forming a palmitate-DHHC intermediate through autopalmitoylation. Upon substrate binding, 
palmitate is transferred from the DHHC to cysteine residues on the substrate though a thioester 
bond (111). While free palmitate is abundantly found in the cell, palmitoyl-CoA is the source of 
palmitate for DHHC enzymes (17, 112). DHHC enzymes are localized on various intracellular 
membrane domains including the Golgi, endoplasmic reticulum, vesicles, and plasma membrane 
(6, 15).  Palmitoylation occurs both at the Golgi, where all palmitoylated proteins are trafficked 
out to cellular domains, and at local membrane domains, raising the possibility that 
palmitoylation may be spatially restricted to occur in proximity of palmitoyltransferases (113, 
114). DHHC expression and localization may also be cell-cycle and tissue dependent (6, 15, 24, 
62, 102, 115, 116). Segregating DHHCs to distinct compartments may serve as nucleating factors 
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to enrich for palmitoylated proteins at distinct membrane domains as in synaptic membranes, 
focal adhesions, and in asymmetrically dividing cells.  This may ensure palmitoylation occurs at 
correct cellular compartments to regulate signaling activity (15, 46, 52, 71, 113). 
Depalmitoylating enzymes make up a much smaller group and the mechanism of 
depalmitoylation remains unclear; however, structural analysis suggests members may belong to 
the larger α/β hydrolase family (6, 9). Acyl-protein thioesterases 1 and 2 (APT1 and APT2) and 
protein palmitoyl-thioesterases 1 and 2 (PPT1 and PPT2) are among the best-studied 
depalmitoylating enzymes (6, 9, 15, 23). APTs are primarily cytosolic proteins and transiently 
localize to membranes to catalyze depalmitoylation (6, 117). While the lack of a defined 
palmitoylation sequence has made identifying specific APT substrates challenging, most 
reversibly-palmitoylated proteins including Ras, MCAM, and Gα subunits, appear to be targets 
(15, 23, 70–72, 75). In contrast, PPTs are thought to be restricted to lysosomes to depalmitoylate 
substrates targeted for degradation (14, 118). The ABHD17 family and orthologs, a subset of the 
α/β hydrolase family, are newly identified depalmitoylating enzymes in mammalian cells and in 
parasites. Whether the substrate pool for ABHD17 enzymes is as diverse as for APTs remains to 
be determined  (12, 18, 119).  
 Palmitoylation may also be regulated at the transcriptional level adding another layer of 
spatio-temporal regulation of protein localization and signaling activity. Micro-RNAs and SNAIL 
have been shown to regulate the expression of palmitoyltransferases and depalmitoylating 
enzymes, and may contribute to dysregulated palmitoylation-mediated protein signaling in 
disease (17, 73, 120, 121). 
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1.5 Function of palmitoylation in protein trafficking, activity, and stability  
 Similar to phosphorylation or ubiquitination, palmitoylation modulates intracellular 
trafficking, activity, and stability, and is regarded as a regulatory switch for proteins (17). The 
role of palmitoylation on polarized protein trafficking has been best characterized in neural cells, 
especially at the synapses (6, 11, 12, 14). Synapses are polarized structures that relay 
electrochemical signals from dendrites to axons between adjacent neurons, and the polarized 
trafficking of synaptic proteins is essential for transmitting these signals between neurons (11, 
122). During neurotransmission, synaptic proteins including PSD-95, AMPA receptors, GABA 
receptors, NMDA receptors, δ-catenin, GRIP1, SynDIG1, SNAP-25, and synaptotagmin-1, 
shuttle between the cytosol, Golgi, vesicles, and synaptic membrane by palmitoylation (11, 14, 
34, 55, 77, 78, 108, 123–127). The immune synapse is similarly polarized when lymphocytes 
come in contact with target cells, which is required to activate lymphocyte function. Like in the 
neural synapse, palmitoylation regulates the shuttling of CD4, CD8, LAT, Lck/Fyn kinases 
between organelles and the synaptic membrane (48, 50, 128–130).  
As mentioned earlier, Ras is palmitoylated at the Golgi to localize to the plasma 
membrane where it interacts with binding partners. Similarly, depalmitoylation keeps Ras 
signaling activity in check by localizing it back to the Golgi where it is inactive (9, 14).  As a 
small GTPase, Ras interacts with effectors PI3K, PLCξ, and RAF at the plasma membrane in its 
active, GTP-bound form. In its inactive GDP-bound form, Ras is localized to the Golgi for 
reactivation (131). Expression of palmitoylation-deficient mutant Ras or small molecule 
inhibition of APTs disrupts Ras activation and intracellular localization (76, 103). Thus, the 
spatiotemporal regulation and distribution of Ras signaling activity requires palmitoylation (103, 
132). Fyn and GPCR activation cycles and intracellular shuttling between the Golgi to the plasma 
membrane are also dependent on palmitoylation in a manner similar to Ras (15, 133). 
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Additional examples of palmitoylation-mediated intracellular trafficking are vast and 
diverse. Protein folding and assembly requires Calnexin, which localizes to endoplasmic 
reticulum-mitochondrial interaction domains and the nucleus through palmitoylation (43, 134). 
Neurochondrin, a negative regulator of Ca++/calmodulin activity in neurons, is targeted and 
trafficked from endosomes to dendrites via palmitoylation (32).  Palmitoylation of Bax, FAS 
death receptor, and Lck kinase mediates translocation from the cytosol to the mitochondria to 
induce apoptosis (29, 42). Insulin-stimulated GLUT4 translocation to the plasma membrane from 
the cytosol is regulated by palmitoylation of the AKT substrate, CLIP-59 (96). Palmitoylation 
also ensures wing disc development by regulating the trafficking of the EGFR ligand Spitz to the 
basolateral membrane of cells (74). Furthermore, inhibition of GAD65 palmitoylation has been 
shown to downregulate the synthesis of GABA, a critical neurotransmitter (77). Sortilin, c-Met, 
and SRC kinases are additional examples of proteins requiring palmitoylation for their 
intracellular trafficking and activity (24, 92, 135, 136).  
 Palmitoylation regulates protein activity by bringing interacting partners into close 
proximity, and can modulate kinase activity through conformational changes (6, 18, 118). EGFR 
is phosphorylated and interacts with signaling effectors on its cytosolic tail, which has been 
shown to be palmitoylated. This is thought to sterically hinder phosphorylation, Grb2 binding, 
and modulate its association with the plasma membrane in the absence of ligand binding (26, 27). 
During glucose uptake in adipocytes, Caveolin2 is phosphorylated by Insulin receptor. Caveolin2 
is also palmitoylated under these conditions, and it is thought the crosstalk between 
palmitoylation and phosphorylation induces a PI3K/Akt- and ERK- signaling cascade that 
promotes adipocyte proliferation and survival (137). FcLR4 is expressed in a subset of B 
lymphocytes and must be palmitoylated to be activated by phosphorylation; this in turn may 
enhance the activation of its substrate, NF-κβ (45). Palmitoylation inactivates Fat by inhibiting its 
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phosphorylation to regulate imaginal wing disc size by Hippo signaling (138, 139). The 
methyltransferase activity and Golgi localization of the transcriptional repressor EZH2 is 
dependent on palmitoylation (60). Palmitoylation induces a conformational shift in the C-terminal 
tail of the ion channel STREX BK to sequester it at the plasma membrane, which activates the 
channel by sterically inhibiting phosphorylation from its negative regulator, Protein Kinase A 
(PKA) (35, 37). 
 Correct protein folding and stability is regulated by crosstalk between ubiquitination and 
palmitoylation (4, 6, 14). Palmitoylated inhibitory SMADs are localized to the plasma membrane 
to target BMP type I receptors for ubiquitination, and modulate TGF-β/BMP signaling (140). 
Palmitoylation of the yeast SNARE protein, TLG1, induces a conformational shift that inhibits 
ubiquitination by facilitating endosomal and Golgi retention (141). Palmitoylation is also 
necessary for the stability of the Hippo pathway transcription factor, TEAD (142). Degradation of 
the anthrax receptor TEM8 is inhibited by palmitoylation, which prevents its targeting to lipid 
rafts where it would otherwise be ubiquitinated (143). In the endoplasmic reticulum, 
palmitoylation of the Wnt co-receptor LRP6 induces a conformational shift in the receptor which 
ensures correct folding of the protein and stability by blocking ubiquitination recognition sites 
(68). 
These examples highlight an essential role for palmitoylation on maintaining signaling 
activity through protein conformation, stability, and binding partner interactions. Extracellular 
stimuli may also vary the intracellular distribution of DHHC enzymes and rate of palmitoylation, 
which may alter protein activity dynamics (15). Furthermore, localizing various DHHCs enzymes 
to distinct cellular compartments may also function as another layer of regulation to modulate 
protein trafficking and activity. Examining these protein distributions within tissues may shed 
insights on how signaling is disrupted in disease. 
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1.6 Palmitoylation function during development  
 Numerous studies, including the works mentioned thus far, have implicated 
palmitoylation as a key spatio-temporal regulator of signaling activity and demonstrate how 
altered palmitoylation is a factor in disease progression. Palmitoylation has been implicated as a 
critical factor in cell fate determination and differentiation in diverse species from plants to 
mammals. Across 31 plant species, DHHC-containing palmitoyl transferases were differentially 
expressed during cell growth and proliferation in different tissues at various developmental 
stages, even within the same plant (144). DHHC13 is thought to modulate Smad6 activity to 
specify ectoderm and mesoderm in zebrafish embryos (65). Palmitoylation has also been 
implicated in reproductive development where DHHC7 drives follicle stimulated hormone 
signaling in Sertoli cells in the testes, to ensure proper spermatogenesis and fertility (145). 
Ovaries expressing a palmitoylation-deficient Dad mutant showed a severe loss in the germline 
stem cell compartment and aberrant TGF-β/BMP signaling in D. melanogaster oocytes (140).  
 DHHC21-mediated palmitoylation of Fyn kinase is required for keratinocyte 
differentiation from epidermal stem cells and hair follicle development in mice, and inhibition of 
DHHC21 resulted in hair follicles with decreased Wnt signaling suggesting palmitoylation 
functions in epithelial homeostasis (25). Additionally, DHHC16 and DHHC5 have been 
suggested as critical factors of stem cell homeostasis in vivo and in vitro, where independent 
studies found these palmitoyltransferases to modulate the switch between multipotency and 
differentiation in neural stem and progenitor cells (63, 86). Palmitoylation of the stem cell 
determinant, Poltergeist, is similarly essential to maintain the stem cell compartment in 
Arabidopsis roots (66).  
 Signaling pathways such as Wnt, Notch, Hippo, and EGFR are tightly coordinated during 
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embryogenesis to promote cell proliferation and differentiation. Modulating the activity of 
signaling pathways promotes organ specification, tissue remodeling, and inhibits aberrant 
proliferation in the adult. These examples identify a critical role for palmitoylation in 
understanding how signaling events are spatio-temporally regulated in response to ligand 
stimulation during embryogenesis and cell fate decisions.  
 
1.7 Palmitoylation during cellular homeostasis and tissue maintenance 
 Because palmitoylated proteins are expressed in most tissues and play a role in 
maintaining homeostasis, any disruptions would be expected to result in developmental defects 
and disease. In addition to DHHC21, epithelial and skeletal tissue function is dependent on 
DHHC13. Loss of function mutations in DHHC13 are associated with various skin disorders 
including alopecia and hypotrichosis in patients. Furthermore, inhibiting DHHC13 activity in 
mice results in gross skeletal defects, decreased bone mass, multiple organ failure, osteoporosis, 
and amyloidosis (25, 146–148). Studies have shown DHHC7 and DHHC17 maintain glucose 
homeostasis in adipocytes in response to insulin signaling, and have identified additional 
palmitoylated substrates adipocytes with proteomic screens (95, 96, 149). Regulation of 
palmitoylation has also been shown to maintain lipid metabolism in liver and muscle, suggesting 
dysregulated palmitoylation may contribute to the development of metabolic disorders such as 
insulin resistance, hyperglycemia, and diabetes (95–97, 150, 151).   
 Gene expression and genomic stability may require palmitoylation, and over a quarter of 
palmitoylated mammalian substrates were identified as nuclear proteins (18, 152) . The 
transcription factor SNAIL, a known driver of epithelial-to-mesenchymal transition in tumors, 
regulates the expression of palmitoyltransferases and depalmitoylating enzymes. As many 
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palmitoylated substrates are also involved in cell polarity and tumor development, SNAIL may 
also affect the function these proteins at both the transcriptional and post-translational level (121, 
153).  Palmitoylation of TEAD, a transcription factor of the Hippo pathway, promotes its 
interaction with transcriptional co-activators YAP and TAZ to mediate Hippo pathway signaling 
during tissue growth and muscle differentiation (101, 142). Lyn kinase, as mentioned earlier, is 
palmitoylated in a cell-cycle dependent manner to inhibit its nuclear localization and prevent 
chromosomal segregation errors (24). Both loss of DHHC16 and pharmacologic inhibition of 
palmitoylation impair DNA damage response in cells by blocking G2/M progression and 
inhibiting ATM-p53 signaling (59). In yeast, palmitoylation of the telomere-binding protein Rif1 
modulates transcriptional silencing and heterochromatin formation (61). Furthermore, silencing 
DHHC8 in radiation-treated mesothelioma cells impairs G2/M progression, and increases 
chromosomal instability and apoptosis (62).  
 In recent years, palmitoylation has been found to play a large part in immune cell fate and 
function in adult tissues. A key step in immune cell function is antigen stimulated protein 
recruitment to the immune synapse. Similar to neuronal synapses, the polarized recruitment of 
many synaptic proteins requires palmitoylation (46). The development of memory B lymphocytes 
and T cells is dependent on palmitoylation of the immunomodulatory receptors FcLR4 and LAT, 
respectively (45, 48). Interestingly, palmitoylation itself is regulated during periods of anergy 
(inactivity) and activation. This is observed with LAT, where its palmitoylation is downregulated 
in anergic T cells (47).  
 Ion-mediated second messenger signaling (calcium- or sodium-mediated) affects the 
function of many enzymes, mediates electric impulses, and is essential for cellular homeostasis. 
Acute regulation of ion channels and pumps is critical to maintain ion homeostasis and flux to 
prevent cellular stress and death (41, 154). Several pumps and channels have been reported to be 
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palmitoylated in various tissues including cardiac and skeletal myocytes, fibroblasts, pancreatic 
β-cells, and embryonic kidney cells.  Additionally, both pharmacologic and genetic perturbation 
of palmitoylation may induce mitochondrial dysfunction and cellular stress (35, 36, 39, 40, 100, 
155). Senescence and apoptosis prevent the accumulation of damaged cells in healthy tissues, and 
studies show evidence of these cellular responses requiring palmitoylation (26, 29, 33, 56, 156) 
26,29,33,56,160
.  
 Extensive studies mentioned in this chapter demonstrate palmitoylation is critical for 
neural development and function. Communication between neurons requires the precise 
coordination of neurite formation and synaptic communication, two processes that both require 
palmitoylation for polarized protein transport as mentioned earlier (157). Dysregulated 
palmitoylation is closely associated with the onset of disorders such as Huntington’s disease, 
Alzheimer’s, anxiety, learning disorders, and schizophrenia (6, 11). Decreased or complete loss 
of DHHC13 and DHHC17 is a major driver of Huntington’s onset and progression (78–80, 158, 
159). In addition to maintenance of synapse function, DHHC7, DHC12, and DHHC21 may be 
misexpressed in Alzheimer’s patients and have been implicated in preventing amyloid plaques 
widely thought to contribute to Alzheimer’s pathogenesis (82, 83, 160). Suppression of DHHC5, 
DHHC8, and DHHC13 activity and expression has also been linked to learning/memory defects, 
schizophrenia, and anxiety disorders (84, 85, 87, 161). 
 Surprisingly, the role of depalmitoylating enzymes on homeostasis and disease remains 
poorly understood. APT1-knockout male mice display significantly decreased body fat according 
to the International Mouse Phenotype Consortium, suggesting APT1 is critical for adipose tissue 
development, homeostasis, and endocrine regulation by adipose tissue (IMPC). Both APT1 male 
and female knockout mice have also been characterized with behavioral defects (IMPC). 
However, the mechanisms by which APT1 maintains behavior and adipose homeostasis remain 
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unknown. Mutations in PPT1 have also been identified and associated with infantile Batten 
disease, a debilitating and fatal neurodegenerative disorder (162). Examining palmitoylation with 
other posttranslational modifications during cellular processes in normal tissues may uncover 
novel regulatory networks for spatiotemporal signaling pathway regulation. 
 
1.8 Palmitoylation function in cancer development 
 Several DHHC enzymes may demonstrate tumor promoting or tumor suppressor 
function, or both, in various cancers. Downregulated expression of DHHC2 has been correlated 
with increased liver metastasis and poor prognosis for gastric and colorectal cancers (90, 163). 
Silencing DHHC3 expression results in suppressed tumor cell migration and invasion through 
decreased Integrin α6β4 palmitoylation, suggesting potential oncogenic function. Conversely, 
DHHC3 may also function as a tumor suppressor as its decreased expression was observed in 
squamous cell cervical cancer and hepatocellular carcinoma (23, 164, 165). Overexpressed 
zHHC5 was reported as a driver of tumor initiation in non-small cell lung cancer cell models, and 
has also been linked to increased tumorigenic and self-renewal potential of p53-mutant glioma 
cells (60, 166).  
 The hormone receptors ERα, ERβ, PR, and AR have been identified as substrates of 
DHHC7, suggesting DHHC7 activity may contribute to the development of hormone-positive 
tumors. Palmitoylation of these receptors facilitates their membrane localization, which has been 
associated with enhanced metastasis and tumorigenic potential through nuclear-independent 
activity (23, 118, 167). Scribble, a regulator of cell polarity and neuronal synaptic function, is a 
membrane-localized tumor suppressor.  Its membrane localization is regulated by DHHC7, and is 
inhibited by the EMT driver SNAIL, which has been shown to transcriptionally repress 
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palmitoylation (53, 153). Future examination of SNAIL on palmitoyltransferase expression may 
reveal greater insights on the localization and expression of tumor suppressors and polarity 
regulators in the developing embryo, adult tissue, and within tumors. Increased DHHC11 
expression has also been associated with aggressive bladder tumors (91). Additionally, DHHC13 
may exhibit tumor suppressor function in melanoma and other skin carcinomas (57, 146). High 
DHHC14 expression is correlated with poor disease outcomes in gastric cancer patients, and was 
found to increase tumor cell invasion and migration (89). Numerous studies have demonstrated 
that palmitoylation of CD9, CD44, CD151, Claudin7, and c-Met, require palmitoylation for 
metastatic potential (88, 92, 93, 164, 168). Palmitoyltransferases may also be differentially 
expressed or serve different functions within the same type of tumor. In breast, ovarian, colorectal 
and blood tumors, DHHC9 expression was downregulated while DHHC20 and DHHC21 are 
overexpressed (23, 94, 167). DHHC14 and DHHC17 may also function differentially as tumor 
suppressors or oncogenic drivers depending on the cancer type (23). 
  Depalmitoylating enzymes, while less studied, also exhibit differing functions in tumor 
development and progression.  APT1 is frequently amplified in various human cancers including 
prostate, uterine, and breast, and this amplification may correlate with poorer survival outcomes 
according to The Cancer Genome Atlas (TCGA). PPT1 is also generally amplified in tumors, 
while APT2 and PPT2 is often deleted or mutated (TCGA). Wnt5a stimulates APT1 
phosphorylation driving its depalmitoylating activity, and expression of APT1 phosphomimetic 
or inactivating mutants implicates APT1 as a regulator of melanoma cell invasion and metastasis, 
thus uncovering a role for depalmitoylation in Wnt5a-overexpressing tumors (70, 169).  
 Protein palmitoylation may also be exploited for therapeutic purposes. For example, 
silencing DHHC20 and EGFR palmitoylation deficient mutants increase the sensitivity to EGFR 
kinase inhibitors in human triple receptor negative breast cancer cells and in Kras mutant cells 
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(26, 170). As mentioned in previous sections, small molecule inhibition of APT1 can disrupt Ras 
membrane localization and downregulate signaling. These molecules have been explored as a 
therapeutic strategy in suppressing Hras and Nras mutant function, although with variable results 
(75, 103, 119, 171). With such a large pool of palmitoylated substrates, identifying bona-fide 
substrate-enzyme pairs may uncover greater therapeutic efficacy and specificity to palmitoylated 
proteins when designing inhibitors or drug combination treatments (23). This strategy has been 
employed to target Ras depalmitoylation is induced upon FKBP12 binding. Pharmacologic 
inhibition of FKBP12 was shown to increase amounts of palmitoylated Ras at the plasma 
membrane, potentially increasing exposure of the active Ras form to inhibitors (172). 
Understanding these enzyme-substrate interactions may also increase our understanding of drug 
resistance in recurrent tumors to uncover areas for therapeutic development. 
 
1.9 Palmitoylation establishes and maintains polarity 
 As mentioned in earlier sections, palmitoylation directs protein polarity within cells and 
across multicellular structures to facilitate and maintain responses to signaling pathways. 
Pharmacologic inhibition and genetic screens identified palmitoyltransferases necessary for the 
formation and growth of polarized root hairs, which are sensory structures in Arabidopsis that 
transmit external stimuli (173). The division and growth of fission yeast occurs along a polarized 
axis, which promotes membrane growth as the yeast increase in size. Establishment this polarized 
axis is dependent on the membrane localization of yeast casein kinase 1γ ortholog, Cki3, which is 
driven by palmitoylation, and yeast expressing palmitoylation-deficient Cki3 show a growth 
delay (31).  
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 In D. melanogaster wing discs, Approximated palmitoylates Fat, a negative regulator of 
growth that restricts Dachs accumulation at apical junctions to inhibit Hippo signaling(138). 
Palmitoylation of Fat negatively regulates its activity, allowing for Dachs accumulation at apical 
junction to drive wing growth (138, 139).  The association of the discs large homolog, MPP3, and 
nectins at apical cell junctions is also dependent on palmitoylation of MPP3; this has also been 
shown necessary to set up the polarity of the developing D. melanogaster embryo (174). The 
formation and stability of polarized cell junctions is crucial in the maintenance of epithelial 
barrier integrity and cell-cell communication (175). Proteins required for cell junction assembly 
and maintenance, including PMP22, Plakophilin, JAM3, SNAIL, and Claudin7, maintain their 
polarized localization and function through direct palmitoylation (51, 52, 54, 88, 99, 121).  
 Cytoskeletal regulators and components have also been reported as palmitoylated 
substrates. Palmitoylation of tubulin has been shown to be essential for membrane association 
during cell division and spindle stability during meiosis in yeast. Whether palmitoylation is also 
required for membrane association in non-dividing cells, polarized trafficking, or if its 
palmitoylation is regulated in a cell-cycle dependent manner remains to be determined (176–178). 
Other small GTPases involved in actin reorganization and vesicular trafficking, such as RhoB, 
RAC1, and RAB10, require palmitoylation to localize at membrane compartments (179–181).  
Additionally, palmitoylation of the master polarity regulator CDC42 is necessary for proper 
dendrite formation and synaptic function in hippocampal neurons (181–183).  
 As polarity is essential to properly localize signaling components in the developing 
embryo and in adults to maintain tissue integrity, it is thought to function as a tumor suppressor 
mechanism (184).  How palmitoylation establishes these interactions may uncover greater 
insights into developmental disease and tumor initiation and progression.  
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1.10 Limitations to studying palmitoylated proteins 
 Palmitoylation was first discovered in 1979, the same year as phosphorylation and four 
years after ubiquitination (185–187). Although it is as common as phosphorylation and 
ubiquitination, very little is known about the biological impact and function of palmitoylation in 
an organism. Detection methods also lag far behind those of phosphorylation and ubiquitination 
(188). 
 Libraries of hundreds of putative palmitoylated substrates have been assembled from 
genomic and proteomic screens from diverse species including Drosophila melanogaster, 
Caenorhabditis elegans, yeast (Schizosaccharomyces pombe, Cryptococcus neoformans, 
Saccharomyces cerevisiae), parasites (Toxoplasma gondii, Plasmodium falciparum), Danio rerio, 
Arabidopsis thaliana and mammals (human: prostate cancer cells, B lymphoid cells, endothelial 
cells, Jurkat T cells, platelets, rat neurons, and mouse T cell hybridoma cells)  (16, 18, 22, 58, 63, 
65, 66, 189–192). Although palmitoylated proteins can be detected with high-throughput means 
such as mass spectrometry, the hydrophobicity, poor solubility, and poor fragmentation of 
palmitoylated proteins has made this approach extremely challenging and prone to false negatives 
(188, 193).  Furthermore, validating bona-fide palmitoylated substrates from libraries is 
predominantly based off generating point mutants and can be an unwieldy endeavor if the number 
of palmitoylated cysteines is unknown or if data sets are large (15, 18). In silico approaches, such 
as Swiss-palm, CSS-palm, and GPS-lipid, predict putative substrates and palmitoylated residues 
based on databases of known palmitoylated sequences (18, 152). Again, the lack of a consensus 
sequence can result in false omission or identification, and thus, in silico approaches should be 
combined with protein structure analysis and biochemical validation.  
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Limitations in protein-based and fluorescence-based have also increased the difficulty of 
identifying and validating palmitoylated substrates. Immunoblotting based approaches in cell and 
tissue lysates can be used identify changes in global palmitoylation or validate specific substrates 
from libraries or in silico methods. When combined with metabolic labeling using azido- or 
alkyne-palmitate analogs, this approach can provide insights into relative palmitate turnover. 
However, metabolic labeling may not be sensitive enough to detection of proteins with a low 
turnover rate, resulting in false reporting as non-palmitoylated (18). Acyl-biotin exchange (ABE) 
and variations have also emerged as a reliable and relatively sensitive detection 
immunoprecipitation-based assay where the reactive thiol on palmitoylated cysteines is replaced 
with a biotin analog (194, 195). Because metabolic labeling is not required in this assay, 
substrates can theoretically be detected regardless of palmitate turnover rates. A variation of the 
ABE assay, known as the acyl-PEG exchange (APE), can also be used to detect the number of 
palmitoylated cysteines on a protein (196). These assays must be rigorously controlled to prevent 
reporting of false-positives, as any reactive cysteine can be detected (11, 16, 177).  
 Another significant setback is the challenge of visualizing the spatio-temporal regulation 
of palmitoylated protein localization and turnover in situ. The lack of a defined consensus 
sequence has made it difficult to design antibodies to palmitoylated domains (15).  Live-imaging 
probes have also not yet been designed to examine temporal dynamics of palmitoylation within 
cells (18). Early imaging approaches have involved fluorescently tagging palmitoyltransferases, 
depalmitoylating enzymes, putative substrates, and corresponding mutants, and imaging 
subcellular localization. TIRF and FRAP microscopy techniques may also assess the localization 
dynamics of palmitoylated substrates by live-cell microscopy (15). Caveats of these imaging 
approaches include an inability to assess is palmitate incorporation in real time, and substrates 
may not have been rigorously validated as palmitoylated (15, 102).  
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 The first successful imaging protocol incorporated metabolic labeling to visualize 
palmitoylated protein localize at plasma membrane, at membrane domains near the mitotic 
spindle, and at the cytokinetic furrow (115). Advancing this protocol, Gao et. al, utilized this 
metabolic labeling approach and combined it with in-situ proximity ligation to detect the 
subcellular localization of palmitoylated Wnts, Hedgehog, and tubulin in fixed cells (177). 
Although prone to false-positives and requiring rigorous validation, these methods have expanded 
our understanding of the spatial organization of palmitoylated effectors.  
Development of small molecule inhibitors can interrogate the role of palmitoylation on 
protein localization, activity, and protein-protein interactions. 2-bromopalmitate (2-BP) is utilized 
as a pan-palmitoyltransferase inhibitor. However, results are inconclusive unless validated with 
genetic knockdown or protein mutants as 2-BP exhibits many off-target effects, and may disrupt 
lipid homeostasis and metabolism at high concentrations (6). Depalmitoylating enzyme inhibitors 
have been more successful in terms of specificity and toxicity. Palmostatin B and Palmostatin M 
are common inhibitors to APT1 and APT2, and to a lesser degree, PPT1 and PPT2 (67, 75, 103, 
132) 
67,75,103,131
. Newly identified piperazine amide compounds ML-348 and ML-349 display high 
sensitivity and specificity for APT1 and APT2, respectively (171). These compounds have been 
employed successfully to examine palmitoylation dynamics in vitro, but not yet used in vivo. 
Although there is still a great deal of information missing including structure analysis, crystal 
structures for APT1, DHHC15, DHHC17, and DHHC20 have been solved (197–199).  This 
structural analysis of DHHCs may uncover new functional insights into the regulation of 
palmitoylation, and may contribute to the development of specific inhibitors with minimal off-
target effects. Additionally, specific inhibitors may be used better understand the biologic 
function, protein interaction, and the dynamic regulation of palmitoylation during development or 
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in disease settings (15, 18). These studies open up future work into developing specific small 
molecule inhibitors for therapeutic strategies in patients. 
 
1.11 Discussion 
 While the function and regulation of palmitoylation on normal cellular functions, 
development, and disease is still rather unclear, palmitoylation is emerging as an essential 
regulatory component of cell signaling. The last few years have seen substantial advances in new 
detection protocols and assay sensitivity, and new studies are identifying novel palmitoylated 
substrates uncovering greater networks of pathway crosstalk. For example, many signaling 
pathways are activated during hair follicle development including Wnt and ERK, and 
palmitoylation is known to play a major role in hair follicle formation (25, 148). In addition to 
Wnt ligands, the signaling pathway components LRP6 and casein kinase have been shown to be 
palmitoylated in the last 15 years (28, 69, 200). How palmitoylation facilitates crosstalk for these 
pathways during hair follicle formation has not been explored. Furthermore, whether 
palmitoylation coordinates the assembly of the Wnt signaling complex and downstream activity 
upon ligand binding in a tissue-dependent context, or even within the same cell, remains an 
unanswered but important question. Additionally, palmitoylation remains poorly defined within 
many critical developmental signaling pathways, as in the case of Notch, where Numb is the only 
component known to be palmitoylated to date (71).  
 Numerous examples in this chapter discuss how palmitoylation facilitates polarized 
protein trafficking between cellular components. Polarity itself is regulated by a complex 
signaling network, yet only a few polarity regulators (e.g. CDC42, Scribble, Rac) have been 
shown to be palmitoylated (53, 179, 181–183).  Palmitoylation of additional polarity components 
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such as PAR proteins and atypical PKC is currently unknown. How palmitoylation coordinates 
these protein interactions to establish polarity in both development and disease will be vital to 
address. The numerous examples in these sections also demonstrate how palmitoylation plays a 
prominent, but relatively unexplored role, in disease onset and highlight areas where 
palmitoylation can be exploited for therapeutic strategies. 
 In this dissertation, I identify a function for APT1 and DHHC20 in establishing polarized 
protein localization during cell division. I also present a role for APT1 in maintaining gene 
signatures and in restricting transcription activity of cell-fate signaling pathways to one daughter 
cell. Furthermore, I interrogate how loss of APT1 decreases the self-renewal potential of breast 
cancer cells and alters the distribution of tumorigenic cells.  With these findings, I present a 
molecular mechanism for palmitoylation-mediated of asymmetric cell division and develop a 
conceptual framework for the maintenance of tumor cell heterogeneity. 
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Figure 1.1 Palmitoylation regulates protein-protein interaction, activity, and stability.  (A to 
C) Palmitoylation promotes the membrane localization of cytosolic proteins (yellow and green) to 
specialized domains (dark blue) to facilitate protein-protein interaction at the membrane (A), can 
sequester cytosolic facing domains or receptors and integral membrane proteins (dark yellow) to 
inhibit effector (pink) binding (B), and may sterically hinder other posttranslational modifications 
such as phosphorylation (red) or ubiquitination (purple) to regulate protein activity and stability 
(C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
 
Figure 1.2 Schematic of palmitoylation. Addition of palmitate to a protein is catalyzed by the 
DHHC class of enzymes localized on endomembrane (e.g. Golgi, endoplasmic reticulum, 
vesicles) or on the plasma membrane, which facilitates membrane association. Depalmitoylating 
enzymes, such as APT1, localize to the membrane to cleave palmitate from substrates via its 
catalytic cleft. This process allows both APT1 and the non-palmitoylated substrate to relocalize to 
the cytosol for recycling or degradation. Adapted from Conibear et. al. (9). 
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CHAPTER 2: IDENTIFICATION OF PALMITOYLATION ON ASYMMETRIC 
PROTEIN SEGREGATION AND TRANSCRIPTIONAL ACTIVITY 
 
From Stypulkowski, et. al. The depalmitoylase APT1 directs the asymmetric partitioning of 
Notch and Wnt signaling during cell division. Sci. Signal. 11, (2018). Reprinted with permission 
from AAAS. 
 
2.1 Summary: 
 Asymmetric cell division is a key mechanism of generating and maintaining diverse cell 
populations, such as stem cells and differentiated cells. Understanding the mechanisms regulating 
the asymmetric localization of cell fate determinants in dividing cells is critical as loss of 
asymmetric division has been associated with the improper expansion of cell populations and 
altered cell fate, resulting in abnormal tissue function.  As discussed in Chapter I, palmitoylation 
is a mechanism of localizing proteins to subcellular membrane domains and can regulate signal 
transduction activity in the cell. However, the function of palmitoylation has not been examined 
in asymmetrically dividing cells. In this Chapter, I show that asymmetric protein localization in 
dividing cells is dependent on palmitoylation. Furthermore, I demonstrate how the 
depalmitoylating enzyme, APT1, and palmitoyltransferase, DHHC20, affect the asymmetric 
expression of transcriptionally regulated GFP reporters between daughter cells. These findings 
introduce lipid modification as a regulator of asymmetric cell division.  
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2.2 Introduction: 
 The development of multicellular organisms relies on the ability to generate functionally 
diverse tissues and organs from an unspecialized stem cell (201). One mechanism of generating 
this cellular heterogeneity is through asymmetric cell division where proteins driving cell 
identity, also known as cell-fate determinants, are unequally distributed between two dividing 
daughter cells. Stem cells are the best-characterized population that undergoes an asymmetric cell 
divisions, producing a self-renewing stem cell and a differentiating daughter cell (5).  
 To initiate an asymmetric division, cell fate determinants must be localized to the plasma 
membrane domains in an orientation perpendicular to the mitotic spindle. This ensures that one 
daughter will inherit more cell-fate determinants upon cytokinesis, which activates a downstream 
transcriptional program that will establish a distinct identity from the other daughter cell (202–
205)
 
(Fig. 2.1). For example, D. melanogaster neuroblasts divide asymmetrically to produce a 
self-renewing neuroblast and a differentiating daughter cell (206, 207). This polarity of cell-fate 
determinants may be induced through extrinsic signals from the extracellular environment or 
through intrinsic polarity (208).  Like developing embryos and normal tissues, cells within tumors 
also vary in functions such as proliferation, survival, self-renewal, quiescence, genomic 
instability, and therapeutic resistance (209–211). However, the contributors of tumor cell 
heterogeneity are not fully understood. Genomic instability, epigenetic alterations, and 
microenvironment interactions are major contributors but are not the only factors (212–214). 
While asymmetric cell division has been commonly thought to function as a tumor suppressive 
mechanism to prevent aberrant stem cell outgrowth (184, 201), its contribution to cellular 
heterogeneity later in tumor development is not fully understood.  
The Notch and Wnt signaling pathways have been shown to be key drivers of cell 
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identity. Numb, an antagonist of Notch, is asymmetrically partitioned to the plasma membrane of 
dividing D. melanogaster neuroblasts, and is inherited by the cell fate to differentiate into a 
neuron (206, 207, 215–217). In mammalian cells, Numb is asymmetrically partitioned in dividing 
mammary epithelial precursors, hematopoietic stem cells, and T-lymphocyte precursors (202, 
218, 219). Likewise, β-catenin, a regulator of canonical Wnt and progenitor cell fate, is 
asymmetrically localized at the plasma membrane of dividing mouse embryonic stem cells and 
C.elegans seam cells, and is excluded from the differentiating daughter cell (204, 220).  
 How Numb and β-catenin are unequally partitioned and retained at the membrane has 
been a major challenge in the field, although several mechanisms have been proposed. Mouse 
embryonic stem cells grown in vitro and C. elegans seam cells divide asymmetrically in response 
to a localized extracellular Wnt stimulus. This reorients the mitotic spindle so that the daughter 
cell closest in proximity to the Wnt signal inherits β-catenin and retains a progenitor fate (220, 
221). Likewise, Numb is segregated asymmetrically along an apical-basolateral axis in dividing 
D. melanogaster neuroblasts, where the apical cell in contact with the neuroepithelium retains a 
progenitor fate, while the basal cell inherits Numb and differentiates (206, 215, 217)
 
(Fig. 2.2 A). 
This would suggest that an extracellular cellular signaling gradient could induce the localization 
in a concentration-dependent manner to induce an asymmetric division, such as in the stem cell 
niche (5, 222, 223). Phosphorylation-induced signal cascade have also been proposed as a 
mechanism of asymmetrically segregating proteins in dividing cells. Studies from several groups 
have shown that aPKC phosphorylates Numb directly to displace it from the apical membrane. 
Additionally, apical aPKC localization is maintained through a negative feedback loop with Lgl, 
a target that is phosphorylated by aPKC to restrict Numb to the basolateral domain (215, 224, 
225)
 
(Fig. 2.2 B).  Partitioning protein degradation machinery between daughter cells has also 
been proposed as a mechanism of asymmetrically segregating proteins (203). In the mouse 
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embryonic stem cells and in C. elegans seam cells mentioned above, β-catenin asymmetry is 
reinforced by the asymmetric segregation of the APC destruction complex (which phosphorylates 
β-catenin) in the daughter cell farthest away from the Wnt signal (204, 220)(Fig. 2.2 C).  It is 
important to note is these mechanisms function together to establish and maintain polarized 
protein localization. What remains unclear is how these asymmetric domains of cell fate 
determinants are maintained at the plasma membrane over the course of cell division long enough 
to result in altered cell fate (Fig. 2.2 D).   
 Although lipid modifications have been shown in Chapter I to regulate protein polarity 
and intracellular localization, the role of lipid modifications on protein localization during 
asymmetric cell division has not been studied. Being a reversible lipid modification, 
palmitoylation could promote asymmetric membrane association and also allow for interaction 
with cytosolic proteins through depalmitoylation (Fig. 2.2 D). Additionally, the role of 
asymmetric cell division on tumor cell heterogeneity remains unclear, although palmitoylation 
has been shown to be a key regulator of protein localization and activity in cancer as discussed in 
Chapter I. Here, I use triple receptor negative breast cancer and osteosarcoma cell lines, derived 
from tumors reported to exhibit a high degree of cellular heterogeneity (226–230), as a 
biochemically tractable model to interrogate the cell-intrinsic factors that regulate asymmetric 
protein localization in dividing cells. I show that not only are Numb and β-catenin asymmetrically 
localized in dividing cancer cells, but also this localization is dependent on APT1 and DHHC20. 
Furthermore, pharmacologic inhibition of APT1 recapitulates this observation. I also show that 
Numb and β-catenin are palmitoylated in cancer cells, and mutation of specific cysteine residues 
on Numb decreases both its palmitoylation and asymmetric localization. Finally, I show that 
Notch- and Wnt- transcriptional GFP reporters are asymmetrically expressed in daughter cells, 
and this asymmetric activation is dependent on APT1 and DHHC20. Together, these results 
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provide evidence for a role for palmitoylation-mediated asymmetric cell division, which may 
contribute to tumor cell heterogeneity.  
 
2.3 Activity of the depalmitoylating enzyme APT1 is required for asymmetric localization of 
proteins 
The depalmitoylating enzyme APT1 has been previously shown to promote the transient 
and asymmetric localization of cell adhesion molecules during interphase in response to 
extracellular signals (70).  To test the hypothesis that APT1 directs the asymmetric localization of 
Notch and Wnt signaling-associated cell fate determinants, during cell division, I first set up 
parameters to score a dividing cell as asymmetric. I examined the spatial organization of Numb, 
β-catenin, and the palmitoylated proteins CD44 and RhoB (93, 180, 231, 232) in fixed cells to 
determine if asymmetric protein localization was a common trait in dividing cells. Using the 
human MDA-MB-231 triple receptor–negative breast cancer cell line, dividing cells were 
identified by immunostaining for acetylated tubulin, a marker of stabilized tubulin structures such 
as the mitotic spindle and cytokinetic midbody (233), and counterstained for Numb, β-catenin, 
CD44, or RhoB. To rule out the possibility of any observed asymmetric protein localization being 
the result of intracellular diffusion, I expressed a control GFP plasmid and assessed GFP 
localization by immunofluorescence. To assess whether a cell divided asymmetrically or not, I 
measured and plotted the percentage difference in the mean fluorescence pixel intensity of the 
protein signal across dividing cells with the following equation (Fig. 2.3 A, B):  
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Generally, most dividing cells displayed symmetric protein localization in the absence of 
exogenous stimuli (Fig. 2.3 B). Individual cells with a percentage difference of 20 or greater were 
scored as asymmetric, and the total percentage of asymmetrically dividing cells was plotted 
according to the equation below:   
 
 
β-catenin was asymmetrically localized in 26.1% of cells, Numb in 29.4% of cells, RhoB 
in 8.3% of cells, CD44 in 12.2% of cells, and GFP in 8.5% of cells (Fig. 2.3 C-G). Treating cells 
with Palmostatin B (PalmB), a pharmacological inhibitor of APT enzymes (234), reduced the 
asymmetric localization of Numb by 3.0-fold (29.4% vs. 9.9%) and β-catenin by 3.3-fold (26.1% 
vs. 8.0%) (Fig. 2.3 C, D). The percentage of cells with asymmetrically localized GFP, CD44, or 
RhoB were not higher than the background percentages observed for β-catenin and Numb 
(approximately 8%), and were unaffected by PalmB treatment (fig. 2.3 E-G). These findings 
suggest that APT enzymes are required for establishing asymmetric localizations of Numb and β-
catenin in dividing cells. 
 
2.4 APT1 and DHHC20 are required for asymmetric Numb and β-catenin localization in 
dividing cells 
Having shown the asymmetric localization of Numb and β-catenin (Fig. 2.3 A, B) can be 
perturbed by inhibiting the activity of depalmitoylating enzymes, I asked whether APT1 was 
specifically required. To address this question, I knocked down APT1 with a short hairpin RNA 
(shRNA) (Fig. 2.4 c). In APT1 knockdown cells, asymmetric localization of Numb was reduced 
by 6-fold (29.4% vs. 4.9%), and asymmetric localization of β-catenin was reduced by 4.1-fold 
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(26.1% vs. 6.4%). Ectopic expression of wild-type human APT1 (APT1
WT
) from a plasmid 
restored asymmetric localization of Numb and β-catenin to baseline control conditions (Fig. 2.4 
E-H). However, ectopic expression of a catalytically inactive mutant form of APT1, in Ser
119
 in 
the catalytic domain is mutated to Ala (APT1
S119A
) (132, 235), failed to rescue asymmetric Numb 
and β-catenin localization (Fig. 2.4 E-H).  This indicates that the catalytic activity of APT1 is 
critical for asymmetric Numb and β-catenin localization.  
Of the 23 DHHC palmitoyltransferases found in mammalian cells, DHHC20 is one of 
three localized to the plasma membrane and is also known to be expressed in MDA-MB-231 
cells, where it palmitoylates EGFR and attenuates EGFR signaling (26, 236). Therefore, I would 
expect it to be available to palmitoylate targets like Numb and β-catenin. To determine whether 
loss of DHHC20 affected protein localization, I knocked down DHHC20 and observed reduced 
asymmetric localization of Numb and β-catenin in a manner similar to APT1 knockdown (Fig. 
2.4 D-F, I, J). 
The dependence of Numb and β-catenin asymmetric localization on APT1 suggests that 
Numb and β-catenin may be palmitoylated. To evaluate protein palmitoylation in native cell 
conditions, I used acyl-biotin exchange (ABE) assays (194). In the ABE assay, proteins are 
treated with N-ethylmaleimide to block free thiol groups, then the Cys-palmitoyl thioester 
linkages are cleaved with hydroxylamine (HAM), and the newly exposed thiol groups are coupled 
to biotin. The modified proteins are then purified with streptavidin (Fig. 2.5 A). Results of ABE 
assays were consistent with Numb and β-catenin being palmitoylated under normal growth 
conditions (Fig. 2.5 B, C). Treating cells with PalmB increased the total amounts of palmitoylated 
Numb and β-catenin (Fig. 2.5 B, C), indicating that palmitoylation of these proteins was inhibited 
in part by APT enzymes. As a negative control, I did not detect palmitoylation of the extracellular 
signal–regulated kinase (ERK), which is not known to bepalmitoylated (Fig. 2.5 D).  
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Together, these findings uncover a role for APT1, and palmitoylation in general, in the 
spatial distribution of the palmitoylated cell fate determinants Numb and β-catenin. 
 
2.5 Asymmetric localization of Numb requires palmitoylation of the phosphotyrosine 
binding domain 
 Although I found β-catenin to be palmitoylated, β-catenin cortical localization is 
mediated through association with cadherins at tight junctions (237, 238). However, the necessity 
of palmitoylation for the membrane localization of β-catenin is unclear and will be discussed in 
later chapter. The conserved phosphotyrosine binding (PTB) domain of Numb is required for 
association of Numb with the plasma membrane and for asymmetric localization of Numb in D. 
melanogaster through mechanisms that are still unknown (239).  I sought to directly test whether 
palmitoylation of Numb is required for its asymmetric localization. Using the palmitoylation 
prediction algorithm CSS-Palm (240) and through identification of solvent-exposed cysteine 
residues within the PTB domain crystal structure (241), three conserved and potentially 
palmitoylated cysteine residues (Cys
37
, Cys
160
, and Cys
165
) were identified and mutated to Ala 
(Fig. 2.6 A, B).  The Numb triple Cys-to-Ala mutant (Numb
AAA
) showed reduced palmitoylation 
as measured by metabolic labeling of cells with palmitic acid azide, which allowed for the study 
of palmitate turnover on Numb (Fig. 2.6 C). Endogenous β-catenin was also metabolically 
labeled with palmitic acid azide, confirming the efficiency of labeling in all reactions (Fig. 2.6 C). 
These results demonstrate that Numb and β-catenin are continuously palmitoylated in MDA-MB-
231 cells. 
Next, I visualized the dynamic localization and segregation of fluorescently labeled Numb 
and APT1 during cell division by live-cell imaging. Because MDA-MB-231 cells shifted from a 
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flat, spread morphology to a raised, rounded morphology out of the imaging plane during cell 
division, I instead utilized U2 OS human osteosarcoma cells, which maintained a consistent 
rounded morphology within the imaging plane during division. U2 OS cells were transduced to 
stably express a mCherry-Histone B (H2B) plasmid, allowing for the unambiguous identification 
of cells undergoing division in real time. Over the course of cell division, cyan fluorescent protein 
(CFP)-tagged APT1
WT
 (APT1
WT
-CFP) and yellow fluorescent protein (YFP)-tagged Numb
WT
 
(Numb
WT
- YFP) exhibited highly dynamic asymmetric localization (Fig. 2.6 D). At the beginning 
of the cell division cycle, Numb
WT
 was concentrated at one end of the cell at the plasma 
membrane, but as daughter cells formed, the localization of Numb shifted to membrane regions at 
and near the cleavage furrow. Finally, as daughter cells separated, Numb was partitioned to the 
plasma membrane of the cell that emerged from the same side of the mother cell to which Numb 
was initially concentrated. APT1
WT
 co-segregated with Numb to membrane regions and retained 
in daughter cells with high Numb signal as indicated by line-scan analysis of YFP and CFP pixel 
intensity along the division axis (Fig. 2.6 D, Movie S1-3, red arrows). This suggests that APT1 
either responds to the same spatial cues as Numb. Alternatively, APT1 may direct Numb 
localization or vice versa. YFP-tagged Numb
AAA
 (Numb
AAA
-YFP) was live-imaged to determine 
the contribution of Numb palmitoylation on its localization.  Numb
AAA
 showed a 1.5-fold reduced 
asymmetric localization in dividing cells as compared to Numb
WT
 (Fig. 2.6 E). Finally, knocking 
down APT1 reduced asymmetric Numb
WT
 localization but did not further reduce the asymmetry 
of Numb
AAA
 (Fig. 2.6 E). These results collectively show that the asymmetric partitioning of 
Numb is actively maintained by a mechanism that requires both APT1-mediated depalmitoylation 
and palmitoylation of Cys
37
, Cys
160
, and/or Cys
165 
within the PTB domain.  
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2.6 APT1 restricts Wnt and Notch transcriptional activity to one daughter cell  
One downstream effect of asymmetrically partitioning cell fate determinants during cell 
division is the activation of different transcriptional networks in the two daughter cells, resulting 
in cells with unique transcriptional profiles (203, 204, 206).  I hypothesized that APT1 could also 
mediate the partitioning of asymmetric transcriptional activity of the Notch and Wnt-β-catenin 
signaling pathways to one daughter cell. I expressed GFP reporter transgenes containing Notch-
activated RBPJ (recombination signal binding protein for immunoglobulin kappa J region) 
binding sites (pGF1-Notch) (242, 243)
 
or Wnt-activated TCF and Lef1 binding sites (pGF1-
TCF/Lef1) in MDA-MB-231 cells, which were then immunostained for GFP and acetylated 
tubulin in daughter cells (Fig. 2.7 A, B). After plotting the distribution of asymmetric divisions as 
described in fig. S1, I observed asymmetric Notch and TCF/Lef1 reporter signal in 22.7% and 
31.7% of daughter cells, respectively. A control GFP reporter containing a minimal CMV 
promoter (mCMV) lacking pathway-specific promoter elements showed symmetric signal in most 
cells and confirmed that the observed asymmetries were dependent on the TCF/Lef1 and Notch 
enhancer elements (Fig. 2.7 C, D). Pharmacologically inhibiting APT1 with PalmB treatment 
reduced asymmetric Notch reporter signal by 3.1-fold (31.7% vs. 10.2%), and Wnt reporter signal 
by 2.6-fold (22.7% vs. 8.7%), respectively (Fig. 2.7 E, F). Knocking down APT1 or DHHC20 
also reduced asymmetric Notch and Wnt reporter signal, indicating that palmitoylation can 
restrict Notch- and Wnt-dependent transcription to one daughter cell (Fig. 2.7 G, H).  
Together these findings suggest palmitoylation may direct the localization of a Wnt 
activating factor and a Notch inhibitory factor to restrict transcription to one daughter cell. 
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2.7 Discussion 
 Maintaining a balance between asymmetric and symmetric divisions is essential for 
sustaining cell diversity during development and in adult tissues. Asymmetric divisions maintain 
the size of cell populations, such as proliferative stem cells and non-dividing differentiated cells, 
to generate cellular heterogeneity and carry out minor tissue repairs. Symmetric divisions are 
expansive and can generate identical cells when rapid growth is necessary, such as during early 
embryogenesis, tissue formation, and large-scale tissue repair after injury. Disruption of 
asymmetric cell division can lead to tissue failure, resulting in disease, due to the aberrant 
overgrowth of the progenitor population as in the case of acute myeloid leukemia and 
neuroblastoma, or may contribute to aging as stem cells lose the ability to self-renew and tissue 
repair cannot be carried out. As fate-determinant proteins direct cell identity, regulating the 
intracellular distribution of these proteins during cell division is necessary to prevent the 
improper expansion of cell populations. 
As mentioned in the introduction, several mechanisms have been proposed to regulate 
asymmetric cell division including protein-protein interaction, asymmetric partitioning of 
degradation machinery, and an extracellular signaling gradient. APT1 was previously shown to 
promote the polarized localization of a palmitoylated substrate in response to extracellular stimuli 
in melanoma cells (70). However, whether lipid modifications were required for asymmetric 
protein localization has not been examined in great detail. Numb has been found by other groups 
to be myristoylated, although inhibition of myristoylation did not disrupt asymmetric Numb 
localization in neuroblasts (239, 244). Palmitoylated β-catenin was identified in several 
palmitoylomes; however, β-catenin palmitoylation remained unconfirmed until recently (60, 71, 
121, 245, 246). The results presented here uncover a cell-intrinsic mechanism through which 
APT1 and DHHC20 restrict the localization of the cell fate determinants β-catenin and Numb and 
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the downstream transcriptional responses to Wnt and Notch signaling to one daughter cell during 
cell division. Importantly, by manipulating APT1 activity, I have demonstrated that the 
asymmetric activation of Notch and Wnt transcriptional reporters can be altered without 
potentially directly affecting the expression of transcription factors or upstream signaling factors. 
Furthermore, palmitoylation directly promotes asymmetric Numb localization as point mutations 
in conserved cysteine residues in Numb inhibit not only its palmitoylation but also its asymmetric 
localization. Because inhibition of palmitoylation reduces the percentage of cells with 
asymmetrically localized cell fate determinants, these results suggest it facilitates a controlled, 
rather than a stochastic, process. 
I found APT1 inhibition did not completely block the asymmetric localization of β-
catenin and Numb, as 8% of dividing cells still were asymmetric. This is similar to the percentage 
of cells with asymmetrically localized GFP that does not respond to APT1 inhibition, suggesting 
palmitoylation is a key contributing factor, but not the sole mechanism, responsible for 
asymmetric protein localization. This palmitoylation-independent asymmetric localization could 
be the effect of previously reported asymmetric partitioning of machinery that maintains protein 
abundance such as the proteasome (203, 247)
 
or protein translation machinery (248, 249), which 
could result in localized differences in protein degradation or synthesis during cell division. 
Wnt5a has been reported to stimulate APT1 depalmitoylating activity, resulting in polarized 
protein localization (70). While the Numb and β-catenin asymmetries shown have occur without 
exogenous ligand stimulation, it is possible that palmitoylated proteins may localize 
asymmetrically in response to extracellular stimulation in a different cancer setting or in a non-
transformed setting.  Future studies will address whether palmitoylation-mediated plasma 
membrane recruitment is initiated by ligand binding, as well as interplay with other proposed 
mechanisms. 
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The observation that both decreased palmitoylation of the Numb
AAA
 mutant, or increased 
palmitoylation of Numb upon APT1 knockdown, can inhibit asymmetric localization suggests it 
is the dynamic, plasma membrane association that promotes asymmetry. Similar to an early study 
characterizing palmitoylated protein localization at the cytokinetic midbody (115), I also find 
APT1 and Numb localize at the midbody, which implies a factor may serve as a recruitment 
platform for palmitoylated proteins. Having shown β-catenin is palmitoylated and asymmetrically 
localized, it is possible that its asymmetric localization may require palmitoylation in a mannaer 
similar to Numb. Additionally, future studies will uncover whether palmitoylation is necessary 
for the stability or activity of Numb or β-catenin, which may affect their intracellular localization 
and asymmetric Notch- or Wnt- transcription. Finally, another area of study would be to 
determine how these palmitoylation-deficient Numb and β-catenin mutants affect Notch and Wnt 
signaling and transcriptional activation.  
Palmitoylation is a dynamic process that regulates cell polarity through cycles of 
membrane association and dissociation. In addition to gradients, asymmetric degradation 
machinery, and phosphorylation cascades, palmitoylation may be another component in that 
stabilizes or establishes asymmetric protein localization during division. The data presented here 
show a previously unstudied role for palmitoylation on asymmetric cell division and potentially 
on cell identity.  
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MATERIALS AND METHODS 
 
Cell Culture 
MDA-MB-231 and U2OS cells were cultured in DMEM + glutamax (Thermo Fisher; Cat. No. 
10566-016) and 10% fetal bovine serum. For drug treatment, cells were treated with DMSO 
(Sigma; Cat. No. D2650), 10μM Palmostatin B (EMD Millipore; Cat. No. 178501) prepared in 
DMSO, or 5 μM 2-bromopalmitate (Sigma; Cat. No. 21604-1G) prepared in DMSO for 16 hours 
before staining or harvesting for cell lysates. Cells were treated with 0.5ug/mL puromycin for 
selection.  
 
Stable cell lines 
HEK cells were transfected with 0.69 μg/μL of a GAG, Rev, and Vsvg mix and 1.42 μg/μL of the 
following plasmids: Scramble control, GFP-PRRL, APT1
WT
 -CFP-Flag-PRRL, APT1 (S119)-
CFP-Flag-PRRL, pGF-Notch-mCMV-GFP-puro (System Biosciences; Cat. No. TR020PA-P), 
pGF-TCF/Lef-mCMV-GFP-puro (System Biosciences; Cat. No.TR013PA-P), or pGF-mCMV-
GFP (System Biosciences; Cat. No. TR011PA-1), for 24 hours with LT-1 transfection reagent 
(Mirus Bio. Cat. MIR2300). The aforementioned APT1 plasmids were designed with short 
hairpin resistant sequences for rescue studies. Virus was collected 72 hours after infection with 
0.5-1mL virus used for stable cell line generation. U2OS cells were infected with APT1
WT
 -CFP-
FLAG or APT1(S119)-CFP-FLAG lentivirus for 24 hours, then recovered in complete DMEM 
for 48 hours prior to cell cultureMDA-MB-231 were infected with the aforementioned lentivirus 
for 24 hours and recovered in complete DMEM for 48 hours prior to cell culture.  
 
Short hairpin design 
shRNA for APT1 
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F 5’- 
CCGGTAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCTATTTTTG
-3’ 
R 5’- 
AATTCAAAAATAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCT
A-3‘ 
 
Alignment of Numb 
Numb sequences from D. melanogaster (P16554), M. musculus (Q9QZS3), D. rerio (Q5FBC1), 
and H. sapiens (P49757) were chosen from UniProt canonical sequences. Alignment was 
performed with Clustal Omega.  Conserved domains were identified by the Conserved Domain 
Database (NCBI). 
 
Mutagenesis 
Site-directed mutagenesis of Numb C37, C160, and C165 to alanine, and APT1 S119 to alanine 
were performed using QuikChange multisite-directed mutagenesis kit (Agilent; Cat. No. 210515). 
Potential palmitoylated cysteines on Numb were identified using CSS-Palm 3.0 developed by 
Zhou. et. al. (240) and analysis of the PTB domain crystal structure.  Mutants were sequence 
verified by the DNA Sequencing Facility at the Perelman School of Medicine, University of 
Pennsylvania. 
 
Live-cell imaging 
MDA-MB-231 cells were not conducive to studying the dynamics of asymmetric localization at 
the plasma membrane by live-imaging, as these cells frequently divided out of the focal imaging 
plane. Thus, U2 OS cells stably expressing mCherry-Histone H2B facilitated protein tracking 
over time and allowed for the study of the dynamics of asymmetric localization at the plasma 
membrane over the course of cell division. U2 OS cells stably expressing APT1
WT
 -CFP-FLAG-
PRRL or APT1
S119A
-CFP-FLAG-PRRL were transfected with 2 μg of NUMBWT-YFP-FLAG- 
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PRRL or NUMB
AAA
-YFP-FLAG- PRRL for 24 hours using LT-1 (Mirus Bio; Cat. No. 
MIR2300) according to manufacturer’s protocol. Cells were imaged 48 hours after transfection in 
HBSS (Life Technologies; Cat. No. 14175079) containing 2% fetal bovine serum, 1 mg/mL 
glutamine, and 20mM HEPES pH 7.4 at 37
o
C. Cells were imaged using the Leica DMI6000 B 
inverted microscope.  
 
Immunofluorescence 
MDA-MB-231 cells were plated on glass coverslips and treated as described. Cells were fixed in 
10% formalin, blocked in 5% BSA in TBS containing 0.1% Triton-X (Roche), incubated in 
primary antibody (β-catenin (9581S; 1:500), CD44 (3570S; 1:500) Cell Signaling Technologies), 
(Numb (ab14140; 1:500)/ APT1 (ab91606; 1:500)/ GFP (ab290; 1:500)/ Caveolin  (ab17052; 
1:500), Abcam), (DHHC20, Sigma; Cat. No. HPA014483; 1:500), (Acetylated tubulin (sc23950), 
RhoB (sc-8048), Santa Cruz), 1:1000), for 1-2 hours at room temperature, incubated in secondary 
antibody (Alexafluor 488 goat anti-mouse (A11001)/ Alexafluor 594 goat anti-rabbit (A11012), 
Life Technologies; 1:1000) for 1 hour at room temperature, and mounted in DAPI-mount 
(Southern Biotech; Cat. No. 0100-20). Cells were imaged using the Leica DMI6000 B inverted 
microscope on 40X magnification and colonies were imaged on 20X magnification.   
 
Western Blotting 
200,000 MDA-MB-231 cells were plated on 60mm tissue culture dishes and were lysed in Tris 
lysis buffer (50mM Tris pH 7.4 buffer, 150mM NaCl, 2% Triton-X, 1μg/ml leupeptin, 1μg/ml 
aprotinin, 2μg/ml pepstatin A). Proteins were run out on 10% acrylamide gel and probed with 
Flag 1:500 (Sigma; Cat. No. F3165), APT1 1:500, Numb 1:1000; β-catenin 1:1000; and DHHC20 
1:1000, at 4ºC, overnight, then incubated in secondary anti-rabbit HRP (Jackson 
Immunoresearch; Cat. No. 211-032-171) or anti-mouse HRP (Jackson Immunoresearch; Cat. No. 
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115-035-003) for 1 hour at room temperature. Blots were developed in Pierce ECL 
Chemilluminescence solution (Thermo Fisher; Cat. No. 32106).  
 
Acyl-Biotin Exchange (ABE) Assay 
The protocol is adapted from Wan et al., 2007 (194) : 200,000 MDA-MB-231 cells were plated 
on 60mm tissue culture dishes and were harvested by scraping in ABE lysis buffer (50mM 
HEPES pH 7.4, 1% Triton X-100, 150mM NaCl, 5mM EDTA, 50mM N-ethyl-maleimide 
(NEM), 1μg/ml leupeptin, 1μg/ml aprotinin, 2μg/ml pepstatin A). Lysates were clarified by 
centrifugation at 15,000 RPM for 10 minutes, and incubated with NEM overnight at 4ºC. The 
samples were m/c precipitated twice then resuspended in 80μL 4%SDS buffer. The samples were 
split in half and 160μL of hydroxylamine buffer (0.7M hydroxylamine pH 7.4, 50mM HEPES pH 
7.4, 0.2% Triton X-100, 150mM NaCl, 5M EDTA) was added to one half of the sample and 
control 0.2% Triton X-100 buffer (50mM HEPES pH 7.4, 0.2% Triton X-100, 150mM NaCl, 
5mM EDTA) was added to the remaining sample and incubated at room temperature for 1hour. 
The samples were m/c precipitated and resuspended in 40μL4%SDS buffer containing 10μM 
Biotin-HPDP (Thermo Fisher; Cat. No. 21341). 160μLof 0.2% Triton X-100 buffer +10μM 
Biotin-HPDP was added and incubated at RT for 1hour. The samples were m/c precipitated and 
resuspended in 20μL of 4%SDS buffer followed by addition of 800μL of 1% Triton X-100 buffer 
(50μL removed for analysis as “input”). 30μL of streptavidin agarose buffer (50mM HEPES pH 
7.4, 0.2% Triton X-100, 150mM NaCl, 5mM EDTA) was added to the remaining sample and 
incubated at room temperature for 1hour. The samples were m/c precipitated and resuspended in 
40μL 4%SDS buffer containing 10μM Biotin-HPDP (Pierce). 160μL of 0.2% Triton X-100 buffer 
+10μM Biotin-HPDP was added and incubated at RT for 1hour. The samples were m/c 
precipitated and resuspended in 20μLof 4% SDS buffer followed by addition of 800μL of 1% 
Triton X-100 buffer (50μLremoved for analysis as “input”). 30μLof streptavidin agarose beads 
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(Thermo Scientific; Cat. No. 20349) were added to the samples and incubated 20 overnight at 4ºC 
rotating. The samples were washed in 1% Triton-X100 buffer and analyzed by SDS PAGE. 
 
Click Chemistry Assay for Palmitoylation  
200,000 U2 OS cells were plated on 60mm tissue culture dishes and were transfected with 2μg 
Numb 
WT
 or Numb
AAA
 YFP-FLAG for 24 hours, labeled with 100μM palmitic acid azide (Life 
Technologies; Cat. No. C10265). Cells were prepared using the Click-IT protein reaction buffer 
(Life Technologies; Cat. No. C10276) according to manufacturer’s protocol and analyzed with 
Western blot as described above.  
 
Quantification and linescan analysis 
Cells were quantified by drawing around the mitotic spindle poles, or around each daughter cell 
in cytokinesis using the Leica LAS AF software as shown in Fig. S1A. Percent difference was 
calculated from the Mean Gray Values generated in Leica LAS AF and calculated as described in 
Fig. S1A. The distribution of acquired percentage differences for each experimental condition 
were plotted as dot plots.  Cells with a percentage difference of 20 or greater were counted as 
asymmetric and plotted in a bar graph. All graphs were generated with Prism software. Linescan 
analysis of pixel intensity was performed on still frames from live-cell movies using ImageJ 
software.  
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Figure 2.1 Schematic of asymmetric cell division. Establishment of intrinsic polarity (green) is 
one of the first steps that must occur for an asymmetric division. Cell fate determinants (red) are 
segregated and aligned perpendicular to the mitotic spindle. Upon cytokinesis, fate determinants 
are unequally inherited by one daughter cell. This unequal partitioning differentially activates 
transcriptional programs, resulting in non-identically fated daughter cells. Adapted from Congdon 
et. al. (250).  
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Figure 2.2 Reported mechanisms of asymmetric cell division to generate non-identical 
daughter cells. (A) Within a stem cell niche, binding of extracellular ligands (yellow) may 
induce mitotic spindle rearrangement and asymmetric recruitment of cell fate determinants (red) 
along the division axis. (B) Phosphorylation-induced inhibitory signaling (green) may restrict the 
asymmetric localization of cell fate determinants (red) to the opposite membrane through intrinsic 
mechanisms or extracellular stimuli. (C) Asymmetric inheritance of proteosome components 
(blue) may also induce the degradation of cell fate determinants upon cytokinesis. (D) In spite of 
this evidence, the mechanisms driving the asymmetric targeting and localization of cell fate 
determinants to the plasma membrane during cell division remain unclear. Adapted from 
Knoblich et. al. (201). 
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Figure 2.3 Scoring method for determining asymmetric divisions. (A) Images of dividing 
MDA-MB-231 cells stained for β-catenin, Numb, RhoB, CD44, or GFP (red), acetylated tubulin 
(green), and nuclei (blue). Regions of interests (ROI), outlined in white dotted line, were obtained 
by drawing around each spindle pole or daughter cell in the image. The mean grey values 
generated from each ROI were used to calculate the percentage difference, which was obtained 
by dividing the difference in ROI values by the average of the ROI values and multiplying by 
100. Scale bars, 15μm. (B) Distribution dot plots showing the difference in mean fluorescence 
pixel intensity of β-catenin (blue), Numb (red), RhoB (green), CD44 (magenta), or GFP (in cells 
expressing an empty GFP vector; yellow) across dividing MDA-MB-231 cells treated with 
PalmB (lighter color) or DMSO (saturated color). The distribution of the percentage differences 
of all quantified cells was plotted, and cells with a difference of >20% (dotted line) were scored 
as asymmetric. n = 106-123 cells scored for each experimental group. Each dot represents a 
single cell. (C to G) Quantification of dividing MDA-MB-231 cells showing asymmetric β-
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catenin (C), Numb (D), RhoB (E), CD44 (F), or GFP (G) localization after treatment with PalmB 
or DMSO control. *P < 0.05, t test. Error bars indicate standard deviation (SD). 
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Figure 2.4 Asymmetric Numb and β-catenin  localization is dependent on APT1 and 
DHHC20. (A and B) Images of dividing MDA-MB-231 cells stained to show endogenous Numb 
(A) and β-catenin (B) in red, acetylated tubulin in green, and nuclei in blue. Arrowheads indicate 
asymmetric localization of Numb and β-catenin. Scale bars, 15 μm. (C) Immunoblot of MDA-
MB-231 cell lysates showing knockdown of endogenous APT1 by shAPT1. Wild-type APT1 
(APT1
WT
-CFP-FLAG) or a catalytically inactive APT1 mutant (APT1
S119A
-CFP-FLAG) were co-
expressed with the shRNA for APT1 rescue experiments. Cells expressing a scrambled (Scr) 
shRNA sequence were used as a negative control for APT1 knockdown, and cells expressing the 
empty vector were used as the negative control for the APT1 rescue experiments. (D) 
Immunoblot of MDA-MB-231 cell lysates when DHHC20 was knocked down with shDHHC20. 
Cells expressing a scrambled (Scr) shRNA sequence were used as a negative control for 
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DHHC20 knockdown. (E and F) Distribution dot plots showing the difference in mean 
fluorescence pixel intensity of endogenous Numb (E) and β-catenin (F) across dividing MDA-
MB-231 cells. The distribution of the percentage differences of all quantified cells 
was plotted, and cells with a difference of >20% (black dotted line) were scored as asymmetric. n 
= 508–to 582 cells scored for each experimental group. Each dot represents a single cell. 
Asterisks indicate statistically significant differences between the indicated groups. (G and H) 
Quantification of the number of dividing MDA-MB-231cells showing asymmetric Numb (G) and 
β-catenin (H) localization when APT1 was knocked down with shAPT1, and when wild-type 
APT1 (APT1
WT
) or the catalytically inactive APT1
S119A
 mutant was coexpressed with shAPT1. 
Cells expressing a scrambled (Scr) short hairpin RNA (shRNA) sequence were used as a negative 
control for APT1 knockdown, and cells expressing the empty vector were used as a negative 
control for the APT1 rescue experiments. (I and J) Quantification of the number of dividing 
MDA-MB-231 cells showing asymmetric Numb (I) and β-catenin (J) localization when DHHC20 
was knocked down with shDHHC20. *P < 0.05, **P < 0.01, ***P < 0.001 analysis of variance 
(ANOVA) (E to H) or t test (I and J).  Error bars indicate SD. 
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Figure 2.5 Numb and β -catenin are palmitoylated in MDA-MB-231 cells. 
 (A) Schematic representation of the ABE assay. Cell lysates are treated with N-ethylmaleimide 
to block free thiol groups. Then, the Cysteine-palmitoyl thioester linkages are cleaved with 
hydroxylamine (HAM), and the newly exposed thiol groups are coupled to biotin. The modified 
proteins are then purified with streptavidin and analyzed by Western blotting. (B to D) 
Immunoblots showing biotin-labeled Numb (B), β -catenin (C), and ERK (D) in MDA-MB-231 
cell lysates after acyl-biotin exchange (ABE) assays and pulldown on streptavidin beads (PD). 
Cells were grown in the presence of either PalmB or vehicle control (DMSO). Input lanes show 
cell lysates before pulldown. Samples without hydroxylamine (−HAM) were negative controls 
for the ABE reactions. 
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Figure 2.6 Palmitoylation and APT1 activity drive Numb localization. (A) Sequence 
comparison of the N terminus of Numb from fruit fly (Drosophila melanogaster), zebrafish 
(Danio rerio), mouse (Mus musculus), and human (Homo sapiens). The phosphotyrosine domain 
(PTB) is highlighted in green, and the putative palmitoylated cysteines are highlighted in yellow. 
Conserved residues are indicated by an asterisk (*). (B) Crystal structure of the D. melanogaster 
Numb PTB domain indicating putative palmitoylated residues C37, C160, and C165 in yellow. 
(C) Immunoblot showing transgenically expressed wild-type Numb (Numb
WT
) or the Numb
AAA
 
mutant and endogenous β-catenin in U2 OS cell lysates after purification of palmitoylated 
proteins. Cells were metabolically labeled with palmitic acid azide or treated with DMSO 
(vehicle control), and then lysates were subjected to click chemistry to convert the palmitic acid 
moiety to biotin, pulled down on streptavidin beads, and used for immunoblotting. Input was 
taken from cell lysates before pulldown. (D) Time-lapse images of dividing U2 OS cells 
coexpressing Numb
WT
-YFP (yellow), APT1
WT
-CFP (blue), and mCherry–Histone H2B (red). 
Fluorescence pixel intensity was measured along the division axis (dashed line), and the 
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corresponding pixel values of Numb (yellow line) and APT1 (blue line) along the division axis 
were plotted on graphs. Red arrowheads on images and graphs indicate the peak Numb and APT1 
pixel intensity at the membrane or cytokinetic midbody. Time is shown in minutes (min). a.u., 
arbitrary units. Scale bars, 15 µm. (E) Quantification of the number of dividing U2 OS cells 
showing asymmetric localization of Numb
WT
-YFP (black bar) and Numb
AAA
-YFP (gray bar) 
when each was coexpressed with shAPT1. Cells expressing a scrambled (Scr) shRNA sequence 
were used as a negative control for APT1 knockdown.  **P < 0.01, t test and ANOVA. Error bars 
indicate SD. 
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Figure 2.7 APT1 restricts Wnt and Notch transcriptional activity to one daughter cell. (A 
and B) Images of cytokinetic MDA-MB-231 cells stained to show the expression of the pGF1-
Notch GFP reporter (A) or pGF-1 TCF/Lef1 GFP reporter (B) (red), acetylated tubulin (green), 
and nuclei (blue). Arrowheads indicate asymmetric localization. Scale bars, 15 µm. (C and D) 
Distribution dot plots showing the difference in mean fluorescence pixel intensity of pGF1-Notch 
reporter (C) or pGF1-TCF/Lef1 reporter (D) across dividing cells. Cells expressing an empty 
pGF1-mCMV GFP reporter were used as a negative control for the reporters. The distribution of 
the percentage differences of all quantified cells was plotted, and cells with a difference of >20% 
(dotted line) were scored as asymmetric. n = 784 to 822 cells scored for each experimental group. 
Each dot represents a single cell. Asterisks indicate statistically significant differences between 
the indicated groups. (E and F) Quantification of dividing MDA-MB 231 cells showing 
asymmetric localization of pGF1-Notch GFP reporter (E) or pGF1-TCF/Lef1 GFP reporter (F) 
(black bars) after treatment with PalmB or DMSO vehicle control. Cells expressing an empty 
pGF1-mCMV reporter (gray bars) were used as a negative control for reporter expression. (G 
and H) Quantification of the number of dividing MDA-MB-231 cells showing asymmetric 
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localization of the pGF1-Notch GFP reporter (G) or pGF1-TCF/Lef1 GFP reporter (H) (black 
bars) when coexpressed with shAPT1, and shDHHC20. Cells expressing an empty pGF1-mCMV 
GFP reporter (gray bars) were used as a negative control for reporter expression, and cells 
expressing a scrambled (Scr) shRNA sequence were used as a negative control for knockdown. 
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, t test (between reporters and pGF1-
mCMV) or ANOVA (C to H). Error bars indicate SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
CHAPTER 3: HOW DOES PALMITOYLATION ESTABLISH PROTEIN POLARITY ? 
From Stypulkowski, et. al. The depalmitoylase APT1 directs the asymmetric partitioning of 
Notch and Wnt signaling during cell division. Sci. Signal. 11, (2018). Reprinted with permission 
from AAAS. 
 
3.1 Summary 
 In Chapter II, I have shown that polarized protein localization is dependent on 
palmitoylation. Several outstanding questions that arise are: 1) what are the factors, if any, that 
may be asymmetrically recruiting Numb and β-catenin to the plasma membrane, and 2) are 
palmitoylation components, e.g. substrates and enzymes, interacting with known polarity-
establishing machinery in cell to maintain these polarized domains? To address the first question, 
I show palmitoylated proteins are localized within close proximity of APT1 and DHHC20. I also 
demonstrate that total palmitoylated proteins are asymmetrically localized and inhibition of APT1 
alters the spatial distribution of palmitoylated proteins within a dividing cell. To determine how 
this palmitoylation-induced polarity is established, I examine how the polarity complex, namely 
CDC42, affects the localization of APT1, Numb, and β-catenin as well as transcription outputs 
between daughter cells. Together, these data provide mechanistic insight into how palmitoylation 
interacts with known cellular machinery to regulate cell polarity. 
 
3.2 Introduction 
 Polarity is the unequal distribution of cellular components within a cell, e.g. proteins, 
mRNA transcripts, vesicles, and organelles (251). This allows the cell to form specialized 
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domains, often at the plasma membrane, which can drive processes such as apical-basolateral 
domain specification, directed cell migration, synapse formation, vesicular trafficking, and 
asymmetric cell division (252, 253). Mechanisms, such as positive feedback loops and directed 
protein trafficking, nucleate molecularly distinct domains at the plasma membrane and regulate 
the rate of protein-membrane association and dissociation to maintain these domains over time (7, 
8, 254)
 
 (Fig. 3.1). What remain unclear are the mechanisms that target and maintain protein 
localization to the plasma membrane.  As reviewed in Chapter I, substrates can be palmitoylated 
at and trafficked from the Golgi to intracellular domains, but can also be palmitoylated locally at 
molecularly distinct membrane domains (113, 114, 236). Thus, palmitoylation may a potential 
mechanism to nucleate protein polarity at the plasma membrane. However, whether additional 
mechanisms interact with palmitoylation to maintain these polarized domains is not fully 
explored.  
 CDC42 is a central regulator of several signaling pathways necessary to establish and 
maintain polarity, including spatially reorganizing actin and microtubules to direct the trafficking 
and fusion of vesicles with the plasma membrane (255–259). Together with Par3, Par6, and 
aPKC, CDC42 has also been implicated in driving asymmetric divisions of the C. elegans zygote, 
D. melanogaster neuroblasts, and budding yeast (1, 260–263). A member of the Ras superfamily 
of small GTPases, CDC42 activity and function is spatially and temporally regulated by cycles of 
GTP hydrolysis and GDP exchange (255, 264, 265). When active, CDC42 is able to bind and 
traffic substrates from the Golgi to the membrane, which are released when GTP is hydrolyzed to 
GDP (264, 266, 267). Extensive studies have shown that disrupting this GTP/GDP exchange 
results in lost of cell polarity (264–266). Thus, cycling between and active and inactive state is 
critical for CDC42 to nucleate and maintain spatially discrete protein domains at the membrane.  
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 CDC42 localization and function is also regulated by lipid modifications (181). CDC42 
has two alternatively spliced exons that result in a prenylated or palmitoylated isoform (182, 183). 
Although, prenylated CDC42 has been conventionally accepted as the widely expressed isoform, 
recent studies are discovering expression of palmitoylated CDC42 in various cell types from 
platelets, T-lymphocytes, and transformed cell lines (121, 190, 191, 246, 268). Like the 
prenylated isoform, palmitoylated CDC42 regulates substrate trafficking between intracellular 
compartments and the plasma membrane; however, the function of palmitoylated CDC42 has 
only been studied during dendrite formation in neurons (183). It is currently unclear if 
palmitoylated CDC42 targets are different from prenylated CDC42, and if the two isoforms 
function redundantly. Additionally, while DHHC8 was shown to palmitoylate CDC42 (85, 269), 
interactions with depalmitoylating enzymes have not been fully explored.  
 The localization of palmitoylation cycle components, e.g. DHHCs, APT1, lipid rafts, and 
palmitoylated proteins, may offer insights into how cell-fate determinants are asymmetrically 
localized in dividing cells. Several studies have shown DHHC enzymes are differentially 
expressed and localized within the cell; these differentially localized palmitoyltransferases are 
thought to establish spatially distinct membrane domains by maintaining local palmitoylation 
cycles (15, 113, 114). APT1 is a primarily cytosolic protein that is recruited to the membrane to 
depalmitoylate substrates in an unclear mechanism (19, 132). In this study, I find APT1 activity is 
required for its own asymmetric localization and the asymmetric localization of total 
palmitoylated proteins in dividing cells. Furthermore, APT1 is observed to localize at membrane 
domains enriched in DHHC20 and palmitoylated proteins. Whether palmitoylation-rich domains 
are established by CDC42 is also poorly defined. Here, I examine the role of CDC42 activity and 
palmitoylation on asymmetric APT1, Numb, and β-catenin localization. With this chapter, I 
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present a mechanism where CDC42 and APT1 function together to nucleate and maintain 
asymmetric protein localization in dividing cells.  
 
3.3 Asymmetric localization of APT1 during cell division requires APT1 catalytic activity 
Having determined that APT1 activity is essential for asymmetric localization of Numb 
and β-catenin, I next examined whether the catalytic activity of APT1 is required for its own 
asymmetric localization. Immunostaining fixed cells showed that endogenous APT1 was 
asymmetrically localized in 22.3% of control cells.  Expressing the catalytically inactive form 
APT1
S119A
 reduced this asymmetric localization by 2.4-fold to 9.4%, whereas expressing APT1
WT
 
had no significant effect (Fig. 3.2 A-C). Knocking down DHHC20 also reduced asymmetric 
APT1 partitioning, suggesting that DHHC20 promotes asymmetric localization of APT1 (Fig. 3.2 
B, D). 
To gain detailed insights into how APT1 activity promotes and maintains the dynamics of 
its own asymmetric localization, I compared the spatiotemporal distribution of ectopically 
expressed APT1
WT
-CFP versus APT1
S119A
-CFP by live-cell imaging in wild-type U2 OS cells. In 
52.6% of dividing cells, APT1
WT
-CFP asymmetry was maintained at the plasma membrane 
through cytokinesis (Fig. 3.2 E, G; Movies S4-5). The asymmetric localization of APT1
S119A
-CFP 
was significantly reduced to 20.6% of cells, similar to the asymmetric localization of GFP-vector 
(16.9%) (Fig. 3.2 F, G; Movies S6-7). Additionally, the catalytically inactive mutant APT1
S119A
-
CFP was not discretely localized to the plasma membrane at the start of division and appeared to 
be stuck at the cytokinetic midbody during cytokinesis (Fig. 3.2 F, Movie S6-7). The data up to 
this point demonstrate that asymmetric localization of APT1 requires its catalytic activity and 
suggest a role for protein depalmitoylation activity at the site of asymmetric protein localization. 
 
 
59 
3.4 Palmitoylating and depalmitoylating enzymes localize asymmetrically with 
palmitoylated proteins during cell division 
  To clarify the purpose of APT1 accumulation at sites of asymmetrically localized 
proteins, I hypothesized that APT1 localizes to regions of high protein palmitoylation. Fixed 
MDA-MB-231 cells were immunostained for Numb and β-catenin, which were asymmetrically 
partitioned to the same region of a dividing cell as APT1.  DHHC20 also displayed asymmetric 
localization to the same membrane region as APT1 (Fig. 3.3 A). Additionally, the distribution of 
APT1 and DHHC20 overlapped with that of caveolin, a palmitoylated protein (270) and lipid raft 
component, at the plasma membrane (Fig. 3.3 B). The results up to this point suggest DHHC20-
mediated palmitoylation of substrates could recruit APT1 to the membrane. 
  The presence of both the depalmitoylating enzyme APT1 and palmitoylating enzyme 
DHHC20 in plasma membrane–associated domains led me to test whether these regions were 
also enriched for palmitoylated proteins. Because there are currently no palmitoylation-specific 
antibodies to visualize the localization of palmitoylated proteins, I modified the ABE assay for 
immunofluorescence and detected asymmetric localization of total palmitoylated proteins, which 
were labeled with biotin, at the cortex of dividing cells (Fig. 3.4 A).  This asymmetric localization 
depended on the activity of APT1, as PalmB treatment decreased the enrichment of palmitoylated 
proteins at the cortex and reduced the percentage of cells showing asymmetric localization of 
palmitoylated proteins by 4.1-fold (31.4% vs. 7.6%). The immunofluorescence signal generated 
by the modified ABE assay was confirmed to be specific to palmitoylated proteins; negative 
control staining of samples in which HAM was omitted from the ABE reaction showed greatly 
reduced signal and symmetric localization (Fig. 3.5 B, C).  To determine the localization of 
palmitoylated proteins relative to APT1 and DHHC20 and whether this asymmetric localization 
was only observed during mitosis, I performed the modified ABE immunofluorescence assay on 
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non-dividing cells. Both APT1 and DHHC20 puncta were localized to regions enriched in 
palmitoylated proteins at membrane ruffles as assessed by confocal microscopy (Fig. 3.5 A, B). 
The data thus far indicate that both APT1 and DHHC20 localize to regions enriched in 
palmitoylated proteins, potentially to establish a local palmitoylation cycle.  
  
3.5 A constitutively active CDC42 mutant promotes asymmetric localization of APT1, 
Numb, and β-catenin during cell division 
I next examined whether APT1-mediated asymmetric protein partitioning functions 
independently of known polarity-establishing mechanisms. The Par-aPKC-CDC42 polarity 
complex promotes the asymmetric cell division in budding yeast, the C. elegans embryo, and in 
D. melanogaster neuroblasts (215, 260, 271). CDC42 and PARD3 (the mammalian homolog of 
Par3) were knocked down to assess the requirement of these factors for APT1, Numb, and β-
catenin localization (Fig. 3.6 A, B). Asymmetric localization of endogenous APT1 was reduced 
by 2.6-fold (22.3% vs. 8.5%) in CDC42 knockdown cells, and by 4.3-fold (22.3% vs. 5.2%) in 
PARD3 knockdown cells (Fig. 3.6 C, D). PARD3 knockdown reduced the asymmetric 
localization of β-catenin, but not that of Numb (Fig. 3.6 E-H). I next asked if CDC42 and APT1 
double knockdown would completely abolish asymmetric Numb and β-catenin partitioning. The 
percentage of cells showing asymmetric partitioning of Numb and β-catenin in the double 
knockdown condition did not further decrease as compared to APT1 or CDC42 single 
knockdown (Fig. 3.6 E-H). This suggests there might be a basal level of asymmetric distribution 
for both of these proteins that is independent of both APT1 and CDC42.  
 I next investigated whether APT1 asymmetric localization depended on CDC42 by 
altering CDC42 activity. In its active GTP-bound state, CDC42 is able to bind substrates and 
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traffic them to the membrane. Once inactivated through GTP hydrolysis, CDC42 is disengaged 
from substrates and released into the cytosol (255, 264, 265). Work from other groups has shown 
that expression of either GTP-locked or GDP-locked mutant forms of CDC42 can interfere with 
CDC42-dependent cellular processes (1, 255, 258, 264–266). I employed live-cell imaging of 
APT1
WT
-CFP and YFP-tagged CDC42 mutants to test the function of CDC42 activity on APT1 
localization. Cells expressing a GTP-locked, constitutively active CDC42 mutant (CDC42
V12
) or 
a GDP-locked, inactive CDC42 mutant (CDC42
N17
) showed reduced asymmetry of APT1
WT
 
during cell division as compared to cells expressing a control GFP vector (Fig. 3.7 A, B). In fixed 
cells, knocking down CDC42 and expressing shRNA-resistant CDC42
V12
 or CDC42
N17
 also 
significantly reduced asymmetric APT1 and β-catenin localization (Fig. 3.7 C, D, F, H). 
Compared to CDC42 knockdown, which had minimal effect, expressing CDC42
V12
 or CDC42
N17
 
resulted in a strong reduction of asymmetric Numb localization (Fig. 3.7 E, G). 
 To demonstrate the requirement of CDC42 cycling activity on APT1 localization in cells, 
I expressed a YFP-tagged constitutively active CDC42 mutant that retains GTP-GDP cycling 
(CDC42
F28L
). Previously shown by other groups to mimic CDC42-mediated effector binding and 
subcellular localization (266), CDC42
F28L
 increase asymmetric APT1
WT 
localization by 1.3-fold 
(52.6% vs. 67.0%) (Fig. 3.7 B).  Expressing shRNA-resistant CDC42
F28L
 in CDC42 knockdown 
cells was sufficient to rescue β-catenin and APT1 asymmetric localization, but only partially 
rescued asymmetric Numb localization in CDC42 knockdown cells (Fig 3.7 C-H). Additionally, 
expression of CDC42
V12
, CDC42
N17
, or CDC42
F28L
 did not significantly alter the low percentage 
of asymmetrically localized catalytically inactive APT1
S119A
 as compared to APT1
WT
 by live-cell 
imaging (Fig. 3.7 B).  These results demonstrate a requirement for the polarity complex and, 
specifically, CDC42 activity in promoting the asymmetric partitioning of APT1 and β-catenin to 
the membrane. However, although Numb asymmetric localization required CDC42 activity, 
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overall it appears to be less dependent than APT1 and β-catenin on the canonical Par-aPKC-
CDC42 polarity complex.  
 
3.6 The reciprocal interaction between APT1 and palmitoylated CDC42 is sufficient to 
promote asymmetric protein partitioning during cell division 
 In addition to cycling between GTP and GDP, CDC42 function is also maintained in part 
by membrane association though a polybasic region and lipid modification of the C-terminal tail 
(255, 258).  There are two known naturally occurring exon splice variants of CDC42 with distinct 
lipid modifications– a solely prenylated splice variant and a dually palmitoylated and prenylated 
splice variant (182). I asked whether either CDC42 splice variant could rescue asymmetric 
protein localization in CDC42 knockdown cells during division by expressing shRNA-resistant 
constructs of the dually lipid modified isoform (CDC42
Palm
) or the solely prenylated CDC42 
(CDC42
Pren
) splice variants (Fig. 3.8 A) and examining the localization of Numb, β-catenin, and 
APT1 in fixed cells. In CDC42 knockdown cells, expressing CDC42
Palm
 was sufficient to fully 
rescue APT1 asymmetry, whereas expression of CDC42
Pren 
appeared to inhibit asymmetric APT1 
localization (Fig. 3.8 A, D). CDC42
Palm
 and CDC42
Pren
 had little effect on asymmetric Numb 
localization in CDC42 knockdown cells. CDC42
Palm
 rescued asymmetric β-catenin localization to 
baseline control conditions, but CDC42
Pren
 had no observable effect (Fig. 3.8 B, C, E, F). These 
results suggest that palmitoylated CDC42 promotes asymmetric localization of specific 
downstream proteins, and APT1 may reciprocally promote asymmetric localization of 
palmitoylated CDC42 during cell division. 
To spatiotemporally visualize CDC42 and APT1 localization during cell division, I 
measured the distribution of APT1
WT
-CFP and CDC42
Pren
-YFP or CDC42
Palm
-YFP by live-cell 
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imaging. CDC42
Palm
 expression increased the percentage of asymmetric APT1
WT
-CFP in dividing 
cells by 1.5-fold (52.6% vs. 82.7%) whereas CDC42
Pren
 suppressed asymmetric partitioning of 
APT1
WT
-CFP by 1.9-fold (52.6% vs. 27.2%). In contrast, neither isoform sufficiently altered 
asymmetric partitioning of catalytically inactive APT1
S119A
 (Fig. 3.9 A). This led me to ask 
whether APT1 was sufficient to promote asymmetric CDC42
Palm
 localization. Both APT1
WT
-CFP 
and CDC42
Palm
-YFP were asymmetric at the plasma membrane early during division, and 
asymmetrically redistributed to the membrane of one daughter cell upon cytokinesis (Fig. 3.9 B).  
As expected, expression of APT1
S119A
 inhibited asymmetric redistribution of CDC42
Palm
-YFP and 
retained CDC42
Palm
-YFP at the cytokinetic midbody (Fig. 3.9 c). I next asked whether CDC42
Palm
 
was endogenously expressed in MDA-MB-231 cells using exon-spanning primers.  I detected the 
endogenous transcript for this palmitoylated CDC42 splice variant by PCR (Fig. 3.10 A, B). 
Furthermore, I detected CDC42 palmitoylation in U2 OS cells by the ABE assay and 
demonstrated that treatment with PalmB increased the amount of palmitoylated CDC42, whereas 
treatment with the palmitoyltransferase inhibitor 2-bromopalmitate (2BP) decreased 
palmitoylation (Fig. 3.10 C). These results suggest that palmitoylated CDC42 could function with 
APT1 in these cells either at a basal level or in a subset of cells to promote asymmetric protein 
localization. 
 
3.7 CDC42 and APT1 interact to maintain differential activation of Notch- and Wnt-
mediated transcription between daughter cells 
 In Chapter II, APT1 was determined to be required for asymmetric activity of Notch and 
Wnt transcription GFP reporters (Fig. 3.11 A). I hypothesized this asymmetric reporter 
expression was regulated by palmitoylation and polarity. To address this hypothesis, CDC42 and 
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DHHC20 were knocked down in MDA-MB-231 cells expressing pGF1-Notch or pGF1-
TCF/Lef1 and asymmetric reporter signal was assessed. Knocking down CDC42 significantly 
disrupted asymmetric Wnt reporter signal, whereas the Notch reporter signal was unchanged, as 
compared to the pGF1-mCMV negative control (Fig. 3.11 C-F).  This was consistent with 
observations of asymmetric Numb localization upon CDC42 knockdown. Additionally, CDC42 
and APT1 may function in the same pathway that stimulates signal-activated transcription 
because double knockdown of APT1 and CDC42 did not appreciably decrease asymmetric Wnt 
or Notch reporter signal over APT1 or CDC42 single knockdown (Fig. 3.11 C-F). Similar to 
APT1, knocking down DHHC20 decreased asymmetric Notch and Wnt reporter expression (Fig. 
3.11 C-F). Together these findings suggest palmitoylation directs the localization of a Wnt 
activating factor and a Notch inhibitory factor to restrict transcription to one daughter cell. 
 
3.8 Discussion 
The data presented show an interdependence of APT1 and CDC42 activity for their own 
asymmetric localization. This interdependence could occur through association of two distinct 
compartments of the plasma membrane: the lipid bilayer and the membrane-associated, cortical 
actin cytoskeleton. CDC42 establishes polarity in cells by spatially reorganizing the cytoskeleton 
to direct vesicular traffic to and fusion with the plasma membrane (255, 257, 259). Because active 
GTP-bound CDC42 is membrane-associated, APT1 could promote the recruitment of 
palmitoylated proteins that also stimulate CDC42 function to the plasma membrane, e.g. the 
CDC42 activator Intersectin, which is also activated by Numb (272). This is consistent with 
current models of diffusible, membrane-bound molecules establishing distinct polarized domains 
at the plasma membrane in a feedforward manner (8, 271).  It has also been hypothesized that the 
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formation of polarized domains can be inhibited if the protein association rate outpaces the 
dissociation rate at the plasma membrane, or vice versa (7, 8). Constitutively GTP-bound 
CDC42
V12
 is unable to release its substrate and has been shown to continuously accumulate at the 
plasma membrane. This results in protein mislocalization at neighboring domains and eventual 
loss of polarity (264, 265). This could explain why polarized membrane domains are sensitive to 
changes in CDC42 protein abundance, activity, and lipid-modification, as demonstrated by the 
findings presented in this chapter.   
An interesting, but unanswered question, is to understand how the activity of 
palmitoylated CDC42 is regulated. Palmitoylated CDC42 and prenylated CDC42 are 95% similar 
in sequence, but appear to be expressed and function differently(181, 182). The palmitoylated 
isoform is stably associated with membrane fractions, while the prenylated isoform is found in 
both the cytosol and membrane. Additionally, palmitoylation inhibits RhoGDIα binding, another 
mechanism of removing Rho GTPases at the plasma membrane in a GTP-hydrolysis independent 
manner (182). Palmitoylated CDC42, but not prenylated CDC42, is required to initiate and 
maintain dendrite formation and branching in neurons (183, 273). Apart from DHHC8 (85, 269), 
little else is known about the DHHCs and depalmitoylating enzymes that regulate palmitoylated 
CDC42 localization and function. How palmitoylation coordinates the palmitoylated CDC42 
membrane localization remains to be determined. Here, I have shown that palmitoylated CDC42 
is asymmetrically localized in dividing cells and this required APT1 activity, suggesting that 
APT1 is one of the depalmitoylating enzymes. Additionally, palmitoylated CDC42 promotes the 
asymmetric localization of β-catenin (and Numb to a lesser degree) potentially in a feedforward 
manner with APT1. The data presented here also demonstrate that the palmitoylated isoform 
transcript is expressed in triple receptor negative breast cancer cells, albeit at a low level. 
Interestingly, expression of palmitoylated CDC42 has been detected in human breast cancer and 
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prostate cancer cell lines (121, 268).  Future studies may reveal whether palmitoylated CDC42 is 
expressed in all cells, but at a level undetectable by conventional means, or if it is re-expressed in 
disease settings which may contribute to aggressive phenotypes. 
Whereas the asymmetric distributions of CDC42 and APT1 appear to be interdependent, 
the depletion of either protein individually has distinct effects on the Wnt and Notch pathways. 
Knocking down CDC42 significantly reduces both APT1 and β-catenin asymmetric localization, 
without significantly affecting the localization of Numb. This would suggest that although 
asymmetric β-catenin and Numb localization require APT1 activity, only the asymmetric 
localization of β-catenin requires asymmetric localization of APT1. CDC42 is known to promote 
canonical Wnt signaling activity by sequestering adenomatosis polyposis coli (APC), a 
component of the β-catenin destruction complex, to the plasma membrane in an actin-dependent 
manner (274, 275). Thus, maintenance of the actin cytoskeleton by CDC42 may be required for 
asymmetric β-catenin localization, but not as much for Numb. As such, the requirement for 
CDC42 may be necessitated by unique mechanisms of Wnt signal activation distinct from a 
requirement for APT1 activity.  
Little is known about the interaction between Notch signaling components and CDC42. 
Notch and CDC42 have been suggested to function in parallel pathways to regulate dendrite 
formation in neurons (276–278). The data presented in the chapter show Numb localization is 
sensitive to CDC42 activity, consistent with a reported interaction between Numb isoforms 5 and 
6 and CDC42 (279). While the results here do not show a strong requirement for CDC42 on 
Notch signaling asymmetry, it is possible other polarity complexes are involved as Notch is 
regulated by the Crumbs polarity complex (280, 281). How palmitoylation may regulate Notch 
localization and activity at the membrane also remains to be determined. 
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 The connection between palmitoylation and polarity is not limited to CDC42. The 
Scribble polarity complex interacts directly with CDC42 and is required for asymmetric cell 
division in D. melanogaster (282, 283).  Two of its members, Scribble and Discs large (also 
known as SAP97 and PSD-95 in mammalian cells), are palmitoylated (53, 107, 153, 284). 
Membrane palmitoylated protein 5 (MPP5), a member of the Crumbs polarity complex and 
regulator of cell junction assembly, is also palmitoylated (174, 285). Future study may reveal 
insights into the regulation of cell polarity by palmitoylation and potential conserved roles. 
Additionally, cell polarity is thought to be a mechanism of tumor suppression (184, 286)
  
and the 
data presented here suggest modulating the palmitoylation cycle is sufficient to disrupt polarity in 
cancer cell lines. It will be interesting to learn whether disrupting palmitoylation of polarity 
regulators, e.g. Scribble and CDC42, is an important step in oncogenic transformation.  
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MATERIALS AND METHODS 
 
Cell Culture 
MDA-MB-231 and U2OS cells were cultured in DMEM + glutamax (Thermo Fisher; Cat. No. 
10566-016) and 10% fetal bovine serum. For drug treatment, cells were treated with DMSO 
(Sigma; Cat. No. D2650), 10μM Palmostatin B (EMD Millipore; Cat. No. 178501) prepared in 
DMSO, or 5 μM 2-bromopalmitate (Sigma; Cat. No. 21604-1G) prepared in DMSO for 16 hours 
before staining or harvesting for cell lysates. Cells were treated with 0.5ug/mL puromycin for 
selection.  
 
Stable cell lines 
HEK cells were transfected with 0.69 μg/μL of a GAG, Rev, and Vsvg mix and 1.42 μg/μL of the 
following plasmids: Scramble control, GFP-PRRL, APT1
WT
 -CFP-Flag-PRRL, APT1 (S119)-
CFP-Flag-PRRL, FLAG- CDC 42 Pren -PRRL, FLAG-CDC42-V12-PRRL, FLAG-CDC42-N17-
PRRL, FLAG-CDC42-F28-PRRL, FLAG-CDC42 Palm-PRRL, pGF-Notch-mCMV-GFP-puro 
(System Biosciences; Cat. No. TR020PA-P), pGF-TCF/Lef-mCMV-GFP-puro (System 
Biosciences; Cat. No.TR013PA-P), or pGF-mCMV-GFP (System Biosciences; Cat. No. 
TR011PA-1), for 24 hours with LT-1 transfection reagent (Mirus Bio. Cat. MIR2300). The 
aforementioned APT1 and CDC42 plasmids were designed with short hairpin resistant sequences 
for rescue studies. Virus was collected 72 hours after infection with 0.5-1mL virus used for stable 
cell line generation. U2OS cells were infected with APT1
WT
 -CFP-FLAG or APT1
S119A
-CFP-
FLAG lentivirus for 24 hours, then recovered in complete DMEM for 48 hours prior to cell 
culture 
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Short hairpin design 
shRNA for PARD3 
F: 5’-
CCGGGCCATCGACAAATCTTATGATCTCGAGATCATAAGATTTGTCGATGGCTTTTTG
-3' 
R: 5'-
AATTCAAAAAGCCATCGACAAATCTTATGATCTCGAGATCATAAGATTTGTCGATGG
C-3' 
 
F: 5'-
CCGGGCCATCGACAAATCTTATGATCTCGAGATCATAAGATTTGTCGATGGCTTTTTG
-3' 
R: 5'-
AATTCAAAAAGCCATCGACAAATCTTATGATCTCGAGATCATAAGATTTGTCGATGG
C-3' 
 
F: 5'-
CCGGAGTCAATTGGATTTCGTTAAACTCGAGTTTAACGAAATCCAATTGACTTTTTTG
-3' 
R: 5'-
AATTCAAAAAAGTCAATTGGATTTCGTTAAACTCGAGTTTAACGAAATCCAATTGAC
T-3' 
 
shRNA for CDC42  
F: 5'-
CCGGCGGAATATGTACCGACTGTTTCTCGAGAAACAGTCGGTACATATTCCGTTTTTG
-3' 
R: 5'-
AATTCAAAAACGGAATATGTACCGACTGTTTCTCGAGAAACAGTCGGTACATATTCC
G-3' 
 
F: 5'-
CCGGTGCTTGTTGGGACTCAAATTGCTCGAGCAATTTGAGTCCCAACAAGCATTTTTG
-3' 
R: 5'-
AATTCAAAAATGCTTGTTGGGACTCAAATTGCTCGAGCAATTTGAGTCCCAACAAGC
A-3' 
 
F: 5'-
CCGGAGATTACGACCGCTGAGTTATCTCGAGATAACTCAGCGGTCGTAATCTTTTTTG
-3' 
R: 
5'AATTCAAAAAAGATTACGACCGCTGAGTTATCTCGAGATAACTCAGCGGTCGTAAT
CT-3' 
 
shRNA for APT1 
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F 5’- 
CCGGTAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCTATTTTTG
-3’ 
R 5’- 
AATTCAAAAATAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCT
A-3‘ 
 
Live-cell imaging 
MDA-MB-231 cells were not conducive to studying the dynamics of asymmetric localization at 
the plasma membrane by live-imaging, as these cells frequently divided out of the focal imaging 
plane. Thus, U2 OS cells stably expressing mCherry-Histone H2B facilitated protein tracking 
over time and allowed me to study the dynamics of asymmetric localization at the plasma 
membrane over the course of cell division. U2 OS cells stably expressing APT1
WT
 -CFP-FLAG-
PRRL or APT1(S119)-CFP-FLAG-PRRL were transfected with 2 μg of YFP-CDC42 Pren-
PCDNA3.1, YFP-CDC42 Palm-PCDNA3.1, YFP-CDC42 V12-PCDNA3.1, YFP-CDC42 N17-
PCDNA3.1, YFP-CDC42 F28-PCDNA3.1, for 24 hours using LT-1 (Mirus Bio; Cat. No. 
MIR2300) according to manufacturer’s protocol. Cells were imaged 48 hours after transfection in 
HBSS (Life Technologies; Cat. No. 14175079) containing 2% fetal bovine serum, 1 mg/mL 
glutamine, and 20mM HEPES pH 7.4 at 37
o
C. Cells were imaged using the Leica DMI6000 B 
inverted microscope. 
 
Immunofluorescence 
MDA-MB-231 cells were plated on glass coverslips and treated as described. Cells were fixed in 
10% formalin, blocked in 5% BSA in TBS containing 0.1% Triton-X (Roche), incubated in 
primary antibody (β-catenin, Cell Signaling Technologies; Cat. No. 9581S; 1:500), (PARD3 
(ab64646; 1:500)/ APT1 (ab91606; 1:500)/ GFP (ab290; 1:500)/ Caveolin  (ab17052; 1:500), 
Abcam), (DHHC20, Sigma; Cat. No. HPA014483; 1:500), (Acetylated tubulin, Santa Cruz; Cat. 
No. sc23950), 1:1000), for 1-2 hours at room temperature, incubated in secondary antibody 
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(Alexafluor 488 goat anti-mouse (A11001)/ Alexafluor 594 goat anti-rabbit (A11012), Life 
Technologies; 1:1000) for 1 hour at room temperature, and mounted in DAPI-mount (Southern 
Biotech; Cat. No. 0100-20). Cells were imaged using the Leica DMI6000 B inverted microscope 
on 40X magnification and colonies were imaged on 20X magnification.   
 
Western Blotting 
200,000 MDA-MB-231 cells were plated on 60mm tissue culture dishes and were lysed in Tris 
lysis buffer (50mM Tris pH 7.4 buffer, 150mM NaCl, 2% Triton-X, 1μg/ml leupeptin, 1μg/ml 
aprotinin, 2μg/ml pepstatin A). Proteins were run out on 10% acrylamide gel and probed with 
PARD3 1:1000, CDC42 1:500 (Cytoskeleton; Cat. No. ACD03), Flag 1:500 (Sigma; Cat. No. 
F3165), APT1 1:500, and DHHC20 1:1000, at 4ºC, overnight, then incubated in secondary anti-
rabbit HRP (Jackson Immunoresearch; Cat. No. 211-032-171) or anti-mouse HRP (Jackson 
Immunoresearch; Cat. No. 115-035-003) for 1 hour at room temperature. Blots were developed in 
Piere ECL Chemilluminescence solution (Thermo Fisher; Cat. No. 32106).  
 
Acyl-Biotin Exchange (ABE) Assay 
The protocol is adapted from Wan et al., 2007 (194) : 200,000 MDA-MB-231 cells were plated 
on 60mm tissue culture dishes and were harvested by scraping in ABE lysis buffer (50mM 
HEPES pH 7.4, 1% Triton X-100, 150mM NaCl, 5mM EDTA, 50mM N-ethyl-maleimide 
(NEM), 1μg/ml leupeptin, 1μg/ml aprotinin, 2μg/ml pepstatin A). Lysates were clarified by 
centrifugation at 15,000 RPM for 10 minutes, and incubated with NEM overnight at 4ºC. The 
samples were m/c precipitated twice then resuspended in 80μL 4%SDS buffer. The samples were 
split in half and 160μL of hydroxylamine buffer (0.7M hydroxylamine pH 7.4, 50mM HEPES pH 
7.4, 0.2% Triton X-100, 150mM NaCl, 5M EDTA) was added to one half of the sample and 
control 0.2% Triton X-100 buffer (50mM HEPES pH 7.4, 0.2% Triton X-100, 150mM NaCl, 
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5mM EDTA) was added to the remaining sample and incubated at room temperature for 1hour. 
The samples were m/c precipitated and resuspended in 40μL4%SDS buffer containing 10μM 
Biotin-HPDP (Thermo Fisher; Cat. No. 21341). 160μLof 0.2% Triton X-100 buffer +10μM 
Biotin-HPDP was added and incubated at RT for 1hour. The samples were m/c precipitated and 
resuspended in 20μL of 4%SDS buffer followed by addition of 800μL of 1% Triton X-100 buffer 
(50μL removed for analysis as “input”). 30μL of streptavidin agarose buffer (50mM HEPES pH 
7.4, 0.2% Triton X-100, 150mM NaCl, 5mM EDTA) was added to the remaining sample and 
incubated at room temperature for 1hour. The samples were m/c precipitated and resuspended in 
40μL4%SDS buffer containing 10μM Biotin-HPDP (Pierce). 160μLof 0.2% Triton X-100 buffer 
+10μM Biotin-HPDP was added and incubated at RT for 1hour. The samples were m/c 
precipitated and resuspended in 20μLof 4%SDS buffer followed by addition of 800μL of 1% 
Triton X-100 buffer (50μLremoved for analysis as “input”). 30μLof streptavidin agarose beads 
(Thermo Scientific; Cat. No. 20349) were added to the samples and incubated 20 overnight at 4ºC 
rotating. The samples were washed in 1% Triton-X100 buffer and analyzed by SDS PAGE. 
 
ABE Assay for Immunofluorescence 
Washes were performed in 1X ABE buffer + 0.2% Triton-X + 0.1% SDS. Cells were seeded onto 
coverslips. Cells were fixed in 10% formalin + 50mM NEM for 10 minutes at room temperature 
and washed once before being incubated overnight in 1X ABE buffer + 0.2% Triton-X + 0.1% 
SDS* + 50mM NEM at 4ºC. The following day, 3 x 15 minute washes were performed. Cells 
were incubated in HA+ or HA- buffer for 2 hours at room temperature, then washed 3 x 
15minutes.  Cells were incubated in Biotin-HPDP buffer for 1 hour at room temperature and 
washed for 3 x 20 minutes. Cells were Incubated in primary antibody (Biotin, 1:500; Abcam; Cat. 
No. ab53494), at 4ºC overnight, and immunofluorescence was performed as described above. 
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Quantification and linescan analysis 
Cells were quantified by drawing around the mitotic spindle poles, or around each daughter cell 
in cytokinesis using the Leica LAS AF software as shown in Fig. S1A. Percent difference was 
calculated from the Mean Gray Values generated in Leica LAS AF and calculated as described in 
Fig. S1A. The distribution of acquired percentage differences for each experimental condition 
were plotted as dot plots.  Cells with a percentage difference of 20 or greater were counted as 
asymmetric and plotted in a bar graph. All graphs were generated with Prism software. Linescan 
analysis of pixel intensity was performed on still frames from live-cell movies using ImageJ 
software.  
 
PCR 
To confirm the expression of FLAG-CDC42 plasmids in shCDC42 MDA-MB-231 cells, I 
isolated RNA and prepared cDNA from FLAG-prenylated CDC42, FLAG-CDC42-V12, FLAG-
CDC42-N17, FLAG-CDC42-F28, FLAG-palmitoylated CDC42 cell lines. PCR reaction was 
performed using 2ug of cDNA, 10X PCR buffer (Sigma; Cat. No. P2192), 10mM dNTPs (Life 
Technologies; Cat. no. 18252015), Taq polymerase (Sigma; Cat. No D1806) and 10μM of 
hCDC42-palm and hCDC42-prenyl primers mentioned above, which are designed to span the 
alternatively spliced exon. The reaction was run out on a 1.4% agarose gel.  
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Figure 3.1 Schematic mechanism of establishing cell polarity. (A to C) The formation of 
polarized protein domains is largely determined by a feedback of membrane association (kON) and 
dissociation (kOFF) rates between the cytosolic pool and the membrane (A). If the kON  outpaces 
the kOFF, protein recruitment to the membrane is sustained and molecules are not removed from 
the membrane quickly enough. This results in loss of distinct protein domains (B). If the kOFF 
outpaces the kON, increased membrane dissociation interferes with the formation of stable 
membrane domains, resulting in an expanded cytoplasmic protein pool and loss of polarized 
domains at the membrane (C). Adapted from Thompson et. al. and Altschuler et. al. (8, 254) 
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Figure 3.2 Asymmetric APT1 localization requires its catalytic activity in MDA-MB-231 
and U2 OS cells. (A) Images of dividing MDA-MB-231 cells stained to show APT1 (red), 
acetylated tubulin (green), and nuclei (blue). Arrowheads indicate asymmetric localization of 
APT1. Scale bars, 15μm. (B) Distribution dot plots showing the difference in mean fluorescence 
pixel intensity of APT1 across dividing MDA-MB-231 cells. The distribution of the percentage 
differences of all quantified cells was plotted, and cells with a difference of >20% (dotted line) 
were scored as asymmetric. (C and D) Quantifications of dividing cells showing asymmetric 
APT1 when APT1
WT
 or APT1
S119A
 was overexpressed (C), or when DHHC20 as knocked down 
with shDHHC20 (D). Cells expressing a scrambled (Scr) shRNA sequence were used as a 
negative control for knockdown or overexpression. n = 302 cells scored for the experimental 
group. Each dot represents a single cell. Asterisks indicate statistically significant differences 
between the indicated groups. (E and F) Time-lapse images of dividing U2 OS cells 
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coexpressing either APT1
WT
-CFP (E) or APT1
S119A
-CFP (F) with mCherry–Histone H2B (red). 
Fluorescence pixel intensity was quantified as in (C). Scale bars, 15 µm. (G) Quantification of the 
number of dividing U2 OS cells showing asymmetric APT1
WT
-CFP or APT1
S119A
-CFP 
localization. Cells expressing an empty green fluorescent protein (GFP) plasmid (Vector) were 
used as a negative control. n = 102 to 143 cells scored for each group from three independent 
experiments. *P< 0.05 and **P < 0.01, t test and ANOVA. Error bars indicate SD. 
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Figure 3.3 APT1 and DHHC20 asymmetrically partitioned with caveolin-rich membrane 
domains during cell division. (A) Images of dividing MDA-MB-231 cells stained to show 
endogenous APT1 (red), Numb, β-catenin, or DHHC20 (green), and nuclei (blue). (B) Images of 
dividing MDA-MB-231 cells stained to show endogenous APT1 (B) or DHHC20 (C), caveolin, 
and nuclei. Asymmetric localization is indicated by arrowheads (A to C). Scale bars, 15 µm. 
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Figure 3.4 Asymmetric localization of bulk palmitoylated proteins in dividing cells is 
inhibited with Palmostatin B. (A) Images of dividing MDA-MB-231 cells treated with PalmB 
or DMSO and stained to show biotin-labeled palmitoylated proteins (red), acetylated tubulin 
(green), and nuclei (blue) by ABE immunofluorescence. Samples without HAM (−HAM) were 
negative controls for the ABE reaction. Scale bars, 15 µm. (B) Distribution dot plots showing the 
difference in mean fluorescence pixel intensity of biotin-labeled palmitoylated proteins. The 
distribution of the percentage differences of all quantified cells was plotted, and cells with a 
difference of >20% (dotted line) were scored as asymmetric. n = 91 to 101 cells scored for each 
experimental group. Each dot represents a single cell. Asterisks indicate statistically significant 
differences between the indicated groups. (C) Quantification of the number of dividing MDA-
MB-231 cells showing asymmetric palmitoylated proteins after treatment with PalmB or DMSO 
control. **P < 0.01 and ****P < 0.0001, t-test and ANOVA. Error bars indicate SD. 
 
 
 
79 
 
 
Figure 3.5 APT1 and DHHC20 localized at the plasma membrane to domains rich in 
palmitoylated proteins. Confocal images of ABE immunofluorescence in non-dividing MDA-
MB-231 cells showing all palmitoylated proteins (green), APT1 (A) or DHHC20 (B) (red), and 
nuclei (blue) by ABE immunofluorescence. White dotted boxes indicated magnified areas shown 
directly below (zoom). Samples without HAM (−HAM) were negative controls for the ABE 
reaction. Scale bars (including zoom), 15 µm.  
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Figure 3.6 Effect of CDC42 and PARD3 knockdown on asymmetric APT1 Numb and β-
catenin localization. (A and B) Immunoblot of MDA-MB-231 cell lysates when CDC42 (A) or 
PARD3 (B) was knocked down by shRNA. All subsequent experiments performed with 
shCDC42 #3 or shPARD3 #3 which showed strongest knockdown efficiency compared to 
GAPDH loading control. (C, E, F) Distribution dot plots showing the difference in mean 
fluorescence pixel intensity of APT1 (C), Numb (E), or β-catenin (F) across dividing MDA-MB-
231 cells. The distribution of the percentage differences of all quantified cells was plotted, and 
cells with a difference of >20% (marked by black dotted line) were scored as asymmetric. n= 
160-186 cells scored for each experimental group. Each dot represents a single cell. Asterisks 
indicate statistically significant differences between the indicated groups. (D, G, H) 
Quantifications of dividing MDA-MB-231 cells showing asymmetric APT1 (D), Numb (G) or β-
catenin (H) with shAPT1, shCDC42, double knockdown using shAPT1 and shCDC42 (DKD), or 
shPARD3. Cells expressing a scrambled (Scr.) shRNA sequence were used as a negative control. 
*P < 0.05; **P < 0.01, ***P < 0.001 T-test (C and D) or ANOVA (E and F- compared to Scr.). 
Error bars indicate standard deviation (SD). 
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Figure 3.7 CDC42 activity promotes asymmetric APT1, Numb, and β-catenin localization. 
(A) PCR of FLAG-CDC42-PRRL plasmid expression of constitutively active CDC42
V12
 or 
CDC42
F28L
, dominant negative CDC42
N17
, the prenylated CDC42 isoform (CDC42
Pren
), and the 
CDC42 isoform that is both palmitoylated and prenylated (CDC42
Palm
). Cells expressing a 
scrambled (Scr) shRNA sequence were used as a negative control for CDC42 knockdown, and 
cells expressing the empty vector were used as the negative control for the CDC42 rescue 
experiments. PRRL plasmid expression was confirmed using primers specific to the plasmid 
sequence. (B) Quantification of the number of dividing U2 OS cells showing asymmetric 
APT1
WT
-CFP or APT1
S119A
-CFP in cells expressing constitutively active (CDC42
V12
 and 
CDC42
F28L
) or dominant-negative (CDC42
N17
) forms of CDC42. n = 152 to 288 cells scored for 
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each group from four independent experiments. (C, E, F) Distribution dot plots showing the 
mean fluorescence pixel intensity of APT1 (C), Numb (E), or β-catenin (F) across dividing cells. 
The distribution of the percentage differences of all quantified cells was plotted, and cells with a 
difference of >20% (dotted line) were scored as asymmetric. n= 430-465 cells scored for each 
experimental group. Each dot represents a single cell. Asterisks indicate statistically significant 
differences between the indicated groups. (D, G, H) Quantification of the number of dividing 
cells showing asymmetric localization of APT1 (D), Numb (G), or β-catenin (H) when 
constitutively active CDC42
V12
 or CDC42
F28L
, or dominant negative CDC42
N17
 was co-expressed 
with shCDC42. Cells expressing a scrambled (Scr) shRNA sequence were used as a negative 
control for CDC42 knockdown, and cells expressing the empty vector were used as the negative 
control for the CDC42 rescue experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 
0.0001, t test (B) and ANOVA (C-H). Error bars indicate SD.  
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Figure 3.8 Palmitoylated CDC42 promotes asymmetric APT1 and β-catenin localization. (A 
to C) Distribution dot plots showing the mean fluorescence pixel intensity of APT1 (A), Numb 
(B), or β-catenin (C) across dividing cells. The distribution of the percentage differences of all 
quantified cells was plotted, and cells with a difference of >20% (dotted line) were scored as 
asymmetric. n= 241-390 cells scored for each experimental group. Each dot represents a single 
cell. Asterisks indicate statistically significant differences between the indicated groups. (D to F) 
Quantification of the number of dividing cells showing asymmetric localization of APT1 (D), 
Numb (E), or β-catenin (F) when CDC42Pren or CDC42Palm was co-expressed with shCDC42. 
Cells expressing a scrambled (Scr) shRNA sequence were used as a negative control for CDC42 
knockdown, and cells expressing the empty vector were used as the negative control for the 
CDC42 rescue experiments. *P < 0.05, **P < 0.01, ***P < 0.001 ANOVA. Error bars indicate 
SD. 
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Figure 3.9 Spatio-temporal localization of CDC42
Palm
 requires APT1
WT 
activity. (A) 
Quantification of the number of dividing U2 OS cells showing asymmetric APT1
WT
-CFP or 
APT1
S119A
-CFP in cells expressing CDC42
Pren
 or CDC42
Palm
 (D). (B and C) Time-lapse images 
of dividing U2 OS cells coexpressing CDC42
Palm
-YFP (yellow) and either APT1
WT
-CFP (B) or 
APT1
S119A
-CFP (C) (blue) and mCherry–Histone H2B (red). Overlapping CFP and YFP signal in 
the merge appears green. Fluorescence pixel intensity was measured along the division axis 
(dashed line), and the corresponding pixel values of CDC42 (yellow line) and APT1 (blue line) 
along the division axis were plotted. Red arrowheads on images and corresponding graphs mark 
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the peak asymmetric CDC42 and APT1 accumulation at the membrane or cytokinetic midbody. 
Time is shown in minutes (min). Scale bars, 15 µm. n = 152 to 288 cells scored for each group 
from four independent experiments. ***P < 0.001 and ****P < 0.0001, t test (A to D) and 
ANOVA (C and D). Error bars indicate SD. 
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Figure 3.10 Expression of palmitoylated CDC42 in MDA-MB-231 and U2 OS cells. (A) 
Schematic of the amino acid sequence of prenylated or palmitoylated CDC42 portraying the 
alternatively spliced exon 6. Exon-spanning primers marked by arrows were designed to amplify 
the alternatively spliced exon to verify expression of the isoforms in MDA-MB-231 cells. (B) 
Expression of endogenous CDC42
Pren
 or CDC42
Palm
 in MDA-MB-231 cells by PCR using the 
primers in (H). (C) Immunoblot showing biotin-labeled CDC42
Palm
-YFP pulled down on 
streptavidin beads (PD) following ABE assay of lysates from MDA-MB-231 cell that were 
treated with PalmB, 2BP, or DMSO control. Input lanes show lysate prior to pulldown. Samples 
without hydroxylamine (-HAM) samples were negative controls for the ABE reactions. 
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Figure 3.11 APT1 restricts Wnt and Notch transcriptional activity to one daughter cell. (A 
and B) Images of cytokinetic MDA-MB-231 cells stained to show the expression of the pGF1-
Notch GFP reporter (A) or pGF-1 TCF/Lef1 GFP reporter (B) (red), acetylated tubulin (green), 
and nuclei (blue). Arrowheads indicate asymmetric localization. Scale bars, 15 µm. (C and D) 
Distribution dot plots showing the difference in mean fluorescence pixel intensity of pGF1-Notch 
reporter (C) or pGF1-TCF/Lef1 reporter (D) across dividing cells. Cells expressing an empty 
pGF1-mCMV GFP reporter were used as a negative control for the reporters. The distribution of 
the percentage differences of all quantified cells was plotted, and cells with a difference of >20% 
(dotted line) were scored as asymmetric. n = 784 to 822 cells scored for each experimental group. 
Each dot represents a single cell. Asterisks indicate statistically significant differences between 
the indicated groups. (E and F) Quantification of the number of dividing MDA-MB-231 cells 
showing asymmetric localization of the pGF1-Notch GFP reporter (G) or pGF1-TCF/Lef1 GFP 
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reporter (H) (black bars) when coexpressed with shAPT1, shCDC42, and shAPT1 and shCDC42 
(DKD). Cells expressing an empty pGF1-mCMV GFP reporter (gray bars) were used as a 
negative control for reporter expression, and cells expressing a scrambled (Scr) shRNA sequence 
were used as a negative control for knockdown. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P 
< 0.001, t-test (between reporters and pGF1-mCMV in E, F) or ANOVA (C to F). Error bars 
indicate SD. 
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CHAPTER 4: ROLE FOR PALMITOYLATION ON TUMOR DEVELOPMENT 
 
From Stypulkowski, et. al. The depalmitoylase APT1 directs the asymmetric partitioning of 
Notch and Wnt signaling during cell division. Sci. Signal. 11, (2018). Reprinted with permission 
from AAAS. 
 
4.1 Summary: 
 The function of asymmetric cell division, if any, on tumor development remains 
contested and poorly understood. In this chapter, I present asymmetric cell division as a potential 
mechanism of maintaining cellular heterogeneity in tumors, and how this heterogeneity may be 
maintained by APT1 and CDC42. RNAseq analysis of MDA-MB-231 cell lines reveals APT1 
expression may play a key role in regulating transcriptional programs involved in cell fate and 
cancer development. I identify a role for APT1 and CDC42 on the clonogenic growth, self-
renewal potential, and population distribution of MDA-MB-231 cells. Together, these findings 
suggest that palmitoylation maintains diverse cell populations, including a pool of self-renewing 
tumorigenic cells, in a multi-cellular context relevant for tumor development. 
 
4.2 Introduction 
 Similar to developing embryos and tissues, tumors also are comprised of phenotypically 
and functionally distinct cell populations (287, 288). Within a tumor, cells can vary in the degree 
of genomic instability, epigenetic modification, invasiveness, proliferative potential, and self-
renewal potential (201, 211). As the different cell populations vary greatly in therapeutic 
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response, tumor heterogeneity presents a major challenge for cancer treatment and is closely 
associated with aggressive disease (5, 184, 287)(Fig. 4.1 A).  
 The ability to form tumors is attributed to tumor-initiating cells, which exhibit properties 
essential for tumor progression such as tumor formation upon single cell transplantation and 
generation of diverse cell populations (227, 287, 289–291) (Fig. 4.1 B). Early studies from patient 
samples revealed leukemia was predominantly comprised of post-mitotic cells, a smaller group of 
highly proliferative cells, and a rare population of quiescent cells (287, 292). Subsequent studies 
aimed at isolating and characterizing tumor-initiating cells from murine models and patient 
derived samples by cell surface marker analysis, and report tumor-initiating cells exhibit stem-
cell like properties such as high proliferative potential, self-renewal, quiescence, and therapeutic 
resistance in vitro and in vivo (213, 226, 227, 293–297). Importantly, cellular heterogeneity is 
observed in tumors grown from a single tumor-initiating cell by surface marker and functional 
analysis (226, 289, 291, 293, 298). Furthermore, tumor-initiating cells may exhibit epigenetic 
alteration, genetic instability, and/or activation of metabolic pathways which promote cell 
survival and heterogeneity after treatment (210, 213, 214, 288, 296). While mechanisms have 
been proposed, the factors generating and maintaining tumor-initiating cells and tumor cell 
heterogeneity still remain unclear and present a challenge for successful, targeted treatment 
strategies. 
 Whether asymmetric cell division promotes tumor cell heterogeneity, as it does during 
development, remains to be determined. Loss of cell polarity is a classic hallmark of oncogenic 
transformation and tumor growth, and polarity regulators have been reported to function as tumor 
suppressors as discussed in Chapter III (184, 251, 286). Consequently, asymmetric cell division is 
also thought of as a tumor suppressor to prevent aberrant cell population expansion, which 
thought to be driven by symmetric cell division within tumors (299–301). However, transformed 
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cells undergo directed cell migration and directed vesicular transport, processes which required 
directional protein localization, suggesting that polarity is not completely disrupted (70, 93). 
Although asymmetrically dividing cells have been observed in cancer cells (218, 219, 294, 299, 
302), whether these divisions contribute to tumor cell heterogeneity and disease progression is 
still poorly understood. 
As reviewed in chapter I, palmitoyltransferases display tumor suppressor or tumor 
promoting function. In contrast, the function of depalmitoylating enzymes within tumors is 
largely unknown. In this chapter, I find APT1 loss-of-function affects the transcriptional profile, 
anchorage independent growth, and self-renewal potential of MDA-MB-231 cells, which are 
derived from an aggressive breast cancer subtype known to exhibit a high degree of cellular 
heterogeneity (298). Moreover, I observe APT1 is required for the expression of Wnt, Notch, and 
Sox2 transcriptional reporters in clonogenically-derived colonies, which may correlate with 
cellular heterogeneity and tumorigenicity. Furthermore, flow cytometry analysis reveals the 
tumor-initiating cell population is decreased upon APT1 knockdown, implicating a function for 
APT1 in the maintenance of tumorigenicity through self-renewal.  With these findings, I identify 
a potential role for APT1-mediated asymmetric cell division on tumor cell heterogeneity. 
 
4.3 APT1 induces Wnt, Notch, and mammary stem cell transcriptional signatures in MDA-
MB-231 triple receptor–negative breast cancer cells 
To date, APT1 has not been shown to drive transcriptional changes in a developmental or 
disease context. To further investigate the observed influence of APT1 on asymmetric Notch and 
Wnt reporter activity, I employed RNA-seq analysis of wild-type control, APT1 knockdown, or 
APT1
WT
-expressing MDA-MB-231 cells to ask whether APT1 influences a Notch or Wnt gene 
 
 
92 
signature (table S1). Gene set enrichment analysis (GSEA) was performed using a pre-ranked list 
of differentially expressed genes and compared APT1
WT
-expressing cells vs. control cells, APT1 
knockdown cells vs. control cells, and APT1
WT
-expressing cells vs. APT1 knockdown cells to 
further examine whether previously defined gene signatures were altered.  In APT1 knockdown 
cells compared to control cells, a high scoring signature [NES (normalized enrichment score) of 
1.46 and a false discovery rate (FDR) q-value of 0.073] was identified that positively correlated 
with genes reported to increase with overexpression of active β-catenin (BCAT_UP.V1_UP), 
suggesting APT1 is inhibitory to β-catenin signaling (Fig. 4.2 A, D). When comparing APT1WT-
expressing cells to control cells, a negative correlation (NES 1.25 and FDR q-value 0.302) was 
identified for a signature of genes reported to decrease upon pharmacologic inhibition of Notch 
(NOTCH_DN.V1_DN). A similar pattern was observed with APT1 knockdown suggesting APT1 
overexpression may function in a dominant negative manner to suppress Notch signaling (Fig. 4.2 
B, D). Additionally, comparing APT1
WT
-expressing cells to APT1 knockdown cells revealed a 
high scoring signature (NES 2.34, FDR q-value=0.0001) for genes reported to increase in 
mammary stem cells (PECE_MAMMARY_STEM_CELL_UP) (Fig. 4.2 C). Visualization of the 
leading-edge genes from the mammary stem cell signature also indicated a strong decrease in 
expression with APT1 knockdown when normalized to control wild-type cells, (Fig. 4.2 E), 
suggestive of an altered cell fate. 
Two additional high scoring signatures found in APT1
WT
-overexpressing cells compared 
to APT1 knockdown cells were signatures for Myc and Cyclin D1 overexpression, both of which 
are maintained by Wnt and Notch signaling (303–305) (NES 2.08, FDR q-value 0.0001; NES 
1.69, FDR q-value 0.014) (Fig. 4.2 F, G). Target genes with high log2FC (fold change) values 
were validated by qRT-PCR. Notable APT1-driven genes included DKK1, BMP4, GATA6, and 
KLF5 (306–308) (Fig. 4.2 H, I; table S1). 
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Based on the high-scoring gene expression signature for mammary stem cells observed in 
APT
WT
-overexpressing cells, it is possible APT1 asymmetrically restricts signaling pathways that 
are activated in stem cells. The transcription factor Sox2 has been implicated in mammary stem 
cell function (309), and expression of a Sox2-responsive reporter (pGF1-SRR2) revealed that its 
asymmetric signal was reduced with APT1 knockdown or PalmB treatment (Fig. 4.3 AD). 
DHHC20, CDC42, or APT1 and CDC42 double knockdown reduced the asymmetric SRR2 
signal (Fig. 4.3 B, C, E). Asymmetric APT1 localization was also observed in dividing mouse 
embryonic stem cells expressing an APT1
WT
 plasmid (Fig. 4. 4). These results imply a role for 
palmitoylation in promoting cell fate–related transcriptional signatures and maintaining 
asymmetric cell division in progenitor cells. 
 
4.4 APT1 and CDC42 maintain unique cell populations in MDA-MB-231 colonies  
 Triple receptor–negative breast tumors, like that from which MDA-MB-231 cells were 
derived, contain subpopulations of cells that vary in proliferative, self-renewing, and tumor-
initiating potential (218, 226, 228). However, whether asymmetric cell division contributes to the 
generation of functionally heterogeneous cells in tumors is unclear. The colony formation assay 
was utilized, which measures the growth and survival of transformed cells in anchorage-
independent conditions. Because only a subset of transformed cells can form colonies, this assay 
may also indicate the degree of heterogeneity within a cell population and may correlate with 
tumor-initiating potential (218, 310). Knocking down APT1 reduced the colony-forming potential 
of MDA-MB-231 cells by 2.3-fold (average colonies counted: shAPT1, 39 vs. Scr, 90), whereas 
expressing APT1
WT
 increased colony numbers by 1.7-fold (average colonies counted: APT1
WT
, 
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152 vs. Scr, 90), suggesting that APT1 is required for the anchorage-independent growth and 
tumorigenic potential of transformed cells (Fig. 4.5 A). 
Self-renewing cells within the colony are expected to form new colonies upon serial 
dissociation and replating, indefinitely. To test whether APT1-mediated asymmetry maintains a 
self-renewing population within colonies, the self-renewal potential of APT1 knockdown or 
CDC42 knockdown MDA-MB-231 cells in colonies was examined over 3 rounds of dissociation 
and replating. APT1 knockdown significantly reduced the number of colonies on the second and 
third plating, suggesting depletion of colony-initiating cells (Fig. 4.5 B). Unexpectedly, CDC42 
knockdown increased the number of colonies formed with each replating compared to control 
cells, suggesting an expansion of a colony-initiating cell population (Fig. 4.5 C). Colonies from 
APT1 and CDC42 double knockdown cells showed reduced replating ability (Fig. 4.5 D), again 
demonstrating that the expansion of this colony-forming population is dependent on APT1. 
Because a significant impairment of proliferation was not observed, this result would suggest that 
the reduced colony-forming potential is not due decreased proliferation under adherent growth 
conditions (Fig. 4.5 E-G).  
Because the increase in colony-forming potential of CDC42 knockdown cells was 
unexpected, I hypothesized this could be caused by increased symmetric divisions of colony-
initiating cells. A subset of highly tumorigenic cells in basal breast cancers have been shown to 
reactivate developmental signaling pathways such as those dependent on Notch, Wnt, or Sox2 
(226, 298, 311, 312). Pharmacologic inhibition of Wnt (with the Porcupine inhibitor IWP2) or 
Notch (with the γ-secretase inhibitor compound E) reduced the self-renewal potential of colonies 
similar to APT1 knockdown or double knockdown (Fig. 4.6 A). Furthermore, APT1 knockdown 
increased Wnt reporter signal and decreased Notch and Sox2 reporter signals in colonies (Fig. 4.6 
B). This is consistent with GSEA analysis in Fig. 4.2 that indicated APT1 knockdown suppressed 
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Notch signaling and promoted β-catenin signaling and pathways active in mammary stem cells. 
Knocking down CDC42 reduced the Notch reporter signal, but increased the Sox2 reporter signal 
in most of the cells within the colony (Fig. 4.6 B). The Sox2 reporter has been previously shown 
to correlate with increased tumorigenicity (298); these results therefore suggest that the increase 
in colony formation caused by CDC42 knockdown is due to an increase in Sox2 transcriptionally-
active cells.  
To address the possibility that APT1 maintains a specific subpopulation of tumorigenic 
cells, colonies were dissociated and analyzed by flow cytometry to test for the cell surface marker 
profile associated with highly tumorigenic cells in breast cancers: CD44 high, CD24 low, and 
Aldehyde dehydrogenase high (CD44
+
/ CD24
lo
/ ALDH
+ 
) (226). The size of the ALDH
+
 
population was higher in APT1 knockdown cells (16.7%) as compared to control (7.3%) or 
CDC42 knockdown (7.8%) cells on the first replating (Fig. 4.7). A difference in the cell 
population distribution was observed in between colony replatings and also, cells grown in 
adherent culture conditions (Fig. 4.8 A).  Further gating the ALDH
+
 population for CD44
+
/CD24
lo
 
cells revealed that knocking down APT1 reduced CD44
+
/CD24
lo 
cells (2.6%), whereas knocking 
down CDC42 increased this population (14.4%), as compared to control cells (5.3%) (Fig. 4.8 B).  
The trend of the number of CD44
+
/CD24
lo
/ALDH
+ 
cells being reduced in the APT1 knockdown 
condition and increased in the CDC42 knockdown condition was sustained on second and third 
replatings (Fig. 4.8 B). A similar pattern was observed to a lesser extent in adherent cells (Fig. 4.8 
B). Consistent with the observed colony phenotypes, these results may explain why CDC42 
knockdown cells form many colonies whereas APT1 knockdown cells are unable to do so. Taken 
together, these findings demonstrate that in an anchorage-independent setting, an APT1-CDC42 
axis maintains the expansion of a self-renewing, tumorigenic cell population and activation of 
transcriptional profiles required to maintain this population. 
 
 
96 
4.5 Discussion 
By manipulating APT1 expression, I have shown that the asymmetric activation of 
Notch, Wnt, and Sox2 transcriptional reporters can be altered without directly affecting the 
expression of transcription factors or upstream signaling factors. The fact that β-catenin and 
Notch gene signatures were not as high-scoring as compared to those of mammary stem cells, 
Myc, and Cyclin D1 signatures may indicate that APT1 directs combinatorial signaling to 
determine cell identity. Myc and Cyclin D1 are canonical downstream transcriptional targets of 
both Wnt and Notch and are also involved in determining mammary stem cell identity (303–305). 
Within the mammary stem cell signature was a notable abundance of ribosomal proteins. A 
similar abundance in ribosomal proteins was also present in the Myc signature, consistent with its 
role in driving ribosomal biogenesis and protein translation in the mammary gland, among other 
tissues, and in cancer (313, 314). Because Myc is a critical factor for mammary stem cell identity 
and function (303), these results would suggest APT1 has a role in translation in mammary stem 
cells. What remains unclear is whether altering APT1 protein amounts induces the expansion of a 
population of cells expressing a mammary stem cell transcriptional signature or induces a de novo 
transcriptional signature in most cells.  Presented here is also evidence of asymmetric APT1 
localization in dividing mouse embryonic stem cells expressing APT1
WT
, suggesting that this 
mechanism may also have a broader and conserved role in development. Future experiments 
including single-cell RNAseq may address these questions.  
Consistent with the concept of changing cell populations, these results suggest that APT1 
is required to maintain a tumorigenic population of breast cancer cells whereas CDC42 appears to 
restrict the size of this population. These findings indicate that APT1 may contribute to the 
activation of transcriptional programs promoting colony-forming potential, whereas CDC42 
could restrict APT1 activity to one daughter during asymmetric division. This would be 
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consistent with the increase in the CD44
+
/ CD24
lo
/ALDH
+
 population in CDC42 knockdown 
colonies.  The implications of this study may be relevant to human disease because APT1 is 
amplified in various cancers, and this amplification is correlated with poor patient prognosis, 
suggesting APT1 could function in the development and progression of human cancers (315, 
316). Although the importance of self-renewing, tumor-initiating, or stem-like cells in cancer is 
still unclear, the question of how tumors maintain and generate cells with diverse properties such 
as metastatic potential, dormancy, and drug resistance is still a critical one. Further exploration of 
the mechanisms that establish and direct asymmetric cell division and promote cellular 
heterogeneity may help us understand tumor development and progression. 
Asymmetric cell division is thought to function as a tumor suppressor by restricting the 
size of cell populations, e.g. stem vs. differentiated cells. Symmetric cell divisions function to 
rapidly expand cell populations, allowing tissues and organisms to develop from a single cell. 
Applying these principles to tumor growth suggests symmetric cell divisions are tumor promoting 
(201, 299, 300). As discussed in the introduction, it is possible that asymmetric and symmetric 
cell division both occur in a tumor. Asymmetric cell divisions may thus be one mechanism of 
generating and maintaining diverse cell populations, while symmetric cell divisions may drive the 
expansion of these various populations.  
Several studies have hypothesized that asymmetric cell divisions may also function to 
segregate damaged or old organelles, proteins, and damaged DNA template to prevent 
propagation of damage that would result in cell cycle arrest or death (5, 31, 205, 247, 286, 317, 
318). Within a tumor, this could maintain a pool of therapy-resistant cells by ensuring that cells 
with sub-optimal fitness (likely to undergo treatment-induced apoptosis) are eliminated. 
Currently, imaging asymmetric cell division in situ remains a major challenge, but the 
development of new imaging assays and identification of asymmetric biomarkers may open up 
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possibilities for imaging explanted patient samples to better understand asymmetric cell division 
in disease progression (287, 294, 319, 320). Understanding all possible factors that generate 
cellular heterogeneity may uncover new insights into the mechanisms of disease recurrence and 
therapeutic resistance. 
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MATERIALS AND METHODS 
 
Cell Culture 
MDA-MB-231 cells were cultured in DMEM + glutamax (Thermo Fisher; Cat. No. 10566-016) 
and 10% fetal bovine serum. For drug treatment, cells were treated with DMSO (Sigma; Cat. No. 
D2650), 10μM Palmostatin B (EMD Millipore; Cat. No. 178501) prepared in DMSO for 16 hours 
before staining or harvesting for cell lysates. Cells were treated with 0.5ug/mL puromycin for 
selection. E14 ESCs were cultured in DMEM Knockout (ThermoFisher. Cat. 10829-018), 15% 
fetal bovine serum, 1% L-glutamine, 1% Pen Strep, 1% Non-essential amino acids, 0.1 mM 2 
mercaptoethanol, 1000 units/mL Leukemia inhibitory Factor (Sigma, Cat. L5158), 1 μM MEK 
I/II Inhibitor (Millipore, Cat. 444966), 3μM GSK3 Inhibitor XVI (Millipore, Cat. 361559) on 
gelatin coated tissue culture plates. 
 
Stable cell lines 
HEK cells were transfected with 0.69 μg/μL of a GAG, Rev, and Vsvg mix and 1.42 μg/μL of the 
following plasmids: Scramble control, pGF-SRR2-mCMV-GFP-puro (System Biosciences; Cat. 
No. SR20071-PA-P) or pGF-mCMV-GFP (System Biosciences; Cat. No. TR011PA-1), for 24 
hours with LT-1 transfection reagent (Mirus Bio. Cat. MIR2300). Virus was collected 72 hours 
after infection with 0.5-1mL virus used for stable cell line generation. E14 ESCs were infected 
with APT1
WT
 -CFP-FLAG lentivirus for 24 hours, then recovered in complete DMEM-knockout 
for 48 hours prior to cell culture. MDA-MB-231 were infected with the pGF-SRR2-mCMV-GFP-
puro or pGF-mCMV-GFP lentivirus for 24 hours and recovered in complete DMEM for 48 hours 
prior to cell culture.  
 
Short hairpin design 
shRNA for CDC42  
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F: 5'-
CCGGAGATTACGACCGCTGAGTTATCTCGAGATAACTCAGCGGTCGTAATCTTTTTTG
-3' 
R: 
5'AATTCAAAAAAGATTACGACCGCTGAGTTATCTCGAGATAACTCAGCGGTCGTAAT
CT-3' 
 
shRNA for APT1 
F 5’- 
CCGGTAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCTATTTTTG
-3’ 
R 5’- 
AATTCAAAAATAGGCCTGTTACATTAAATATCTCGAGATATTTAATGTAACAGGCCT
A-3‘ 
 
 
Immunofluorescence 
 
MDA-MB-231 cells were plated on glass coverslips and treated as described. Cells were fixed in 
10% formalin, blocked in 5% BSA in TBS containing 0.1% Triton-X (Roche), incubated in 
primary antibody (GFP (ab290), Abcam; 1:500) (Acetylated tubulin, Santa Cruz; Cat. No. 
sc23950; 1:1000), for 1-2 hours at room temperature, then incubated in secondary antibody 
(Alexafluor 488 goat anti-mouse (A11001)/ Alexafluor 594 goat anti-rabbit (A11012), Life 
Technologies; 1:1000) for 1 hour at room temperature, and mounted in DAPI-mount (Southern 
Biotech; Cat. No. 0100-20). ESCs were cultured without LIF, MEK or GSK inhibitors for 24 
hours before staining with 1:1000 anti-GFP (ab290) as described. Cells were imaged using the 
Leica DMI6000B inverted microscope on 40X magnification and colonies were imaged on 20X 
magnification.   
 
Quantification and line scan analysis 
Cells were quantified by drawing around the mitotic spindle poles, or around each daughter cell 
in cytokinesis using the Leica LAS AF software as shown in Fig. S1A. Percent difference was 
calculated from the Mean Gray Values generated in Leica LAS AF and calculated as described in 
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Fig. S1A. The distribution of acquired percentage differences for each experimental condition 
were plotted as dot plots.  Cells with a percentage difference of 20 or greater were counted as 
asymmetric and plotted in a bar graph. All graphs were generated with Prism software. Linescan 
analysis of pixel intensity was performed on still frames from live-cell movies using ImageJ 
software.  
 
Colony Assays 
MDA-MB-231 cells were plated on 6-well, low adhesion plates (Corning; Cat. No. 3471) in 2mL 
of WIT-P plus serum-free supplement growth media (Cellaria; Cat. No. 00-0045-500) containing 
20ng/mL FGF (Life Technologies; Cat. No. PHG0024), 20ng/mL EGF (Life Technologies; Cat. 
No. PHG0311), and 10 μg /mL heparin (StemCell Technologies; Cat.  No. 07980).  Each well 
contained 4,000 cells.  Cells were treated with 1 μM GSI (Compound E; Millipore; Cat. No. 
565790), 5 μM IWP2 (StemCell Technologies; Cat. No. 72124), or DMSO (Sigma; Cat. No. 
D2650) and grown for 7 days before counting. For replating, cells were grown into colonies as 
described. On Day 7, colonies were spun down at 1000rpm x 5min, resuspended in 0.05% 
Trypsin-EDTA, reconstituted in growth media, and plated as described above. This process was 
repeated for three replatings in duplicate. 
 
Proliferation Assays 
15,000 MDA-MB-231 cells were plated on a 12-well dish (ThermoFisher; Cat. No. 087723A). At 
24, 48, and 72 hours, cells were washed with 1X PBS, trypsinized, and spun at 1000rpm X 5 
minutes. Pellets were resuspended in DMEM and counted by a hemocytometer. 
 
RNA Isolation and Quantitative Real-Time PCR 
Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen; Cat. No. 74104) and cDNA 
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was synthesized from 2,000ng total RNA using SuperScript III First-Strand Synthesis SuperMix 
(Life Technologies; Cat. No. 18080400). qRT-PCRs were performed in triplicate using standard 
SYBR green reagents and protocols on a StepOnePlus Real-Time PCR system (Applied 
Biosystems). Target genes with high log2FC values were chosen for validation. The target mRNA 
expression was quantified using 
ΔΔ
Ct method and normalized to GAPDH expression. The 
following primers were used for validation: 
hDKK1 
F: 5’- CAGGCGTGCAAATCTGTCT – 3’ 
R: 5’- AATGATTTTGATCAGAAGACACACATA – 3’ 
 
hFGF5 
F: 5’- CCCAGAATCAGCCCTACAAG – 3’ 
R: 5’- GAGGAGGAAGGACAAGCTCA – 3’ 
 
hGATA6 
F: 5’- GCAAAAATACTTCCCCCACA – 3’ 
R: 5’- TCTCCCGCACCAGTCATC – 3’ 
 
hKLF5 
F: 5’- CTGCCTCCAGAGGACCTG – 3’ 
R: 5’- TCGTCTATACTTTTTATGCTCTGGAAT – 3’ 
 
hITGB4 
F: 5’- TCAGCCTCTCTGGGACCTT – 3’ 
R: 5’- TCCTTATCCACACGGACACA – 3’ 
 
hBMP4 
F: 5’- TCCACAGCACTGGTCTTGAG – 3’ 
R: 5’- TGGGATGTTCTCCAGATGTTCT – 3’ 
 
 
hPTK7 
F: 5’- CAGAGGACTCACGGTTCGAG – 3’ 
R: 5’- TACCAGGGTCTCTGCCACTC – 3’ 
 
hGAPDH 
F: 5’- ACA CCA TGG GGA AGG TGA AG-3’ 
R: 5’-AAG GGG TCA TTG ATG GCA AC -3’ 
 
hCDC42 palm  
F: 5’-TGGAGTGTTCTGCACTTACA-3; 
R: 5’-GAATATACAGCACTTCCTTTTGGG-3’ 
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hCDC42 prenyl  
F: 5’-AGGCTGTCAAGTATGTGG-3’ 
R: 5’-TAGCAGCACACACCTGCG-3’ 
 
RNA Isolation and analysis for RNA-seq 
Total RNA was harvested from MDA-MB-231 control, APT1
WT
-overexpressing or shAPT1 cells 
using the RNeasy RNA isolation kit (Qiagen; Cat. No. 74104). 100ng of RNA was used to 
generate cDNA libraries with the Illumina TruSeq mRNA Library Prep Kit for NeoPrep library 
preparation system (Illumina; Cat. No. NP-202-1001) and reaction was performed on a 
NextSeq500 sequencer. Analysis was prepared by the DNA Sequencing Facility at the Perelman 
School of Medicine, University of Pennsylvania as follows: estimated transcript levels were 
ranked with Salmon, TX Import was used to condense transcript levels to gene intensity, and 
Deseq2 was used to calculate statistical levels for each condition. The scaled values (determined 
by DeSeq2) were input to Gene Set Enrichment Analysis software (Broad Institute) and analyzed 
against the C2 Chemical and Genetic perturbations, C6 Oncogenic, and Hallmark signatures gene 
matrix applying classic enrichment statistic. Heat maps were generated by taking the log2 values 
with an offset of 1 for all conditions and targets were chosen by taking the leading-edge targets 
from GSEA BCAT, NOTCH, and mammary stem cell sets. The average of the 3 control wild-
type values were subtracted from each individual value. Values were clustered for samples and 
genes using Euclidean similarity measure with average linkage.  
 
Flow cytometry  
Adherent non-confluent MDA-MB-231 cells or colony-dissociated cells were treated to detect 
ALDH activity using the ALDEFLUOR assay (Stem Cell Technologies; Cat. No. 01702) 
according to manufacturer’s protocol.  Diethylaminobenzaldehyde (DEAB) was used as a 
negative control to set ALDH + gates. Cells were stained for surface markers with CD44-APC 
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(BD Biosciences; Cat. No. 560890), CD24-PE (BD Biosciences; Cat. No. 560991), and 
Live/Dead Violet (Thermo Fisher; Cat. No. L34963) for viability. Compensation was performed 
using Ultra Comp beads (Thermo Fisher; Cat. No. 01-2222-41). Experiments were run on the 
Attune NxT flow cytometer system (Life Technologies) and analyzed with FlowJo software. 
ALDH+ cells (Fig. S7) were gated for CD44
+
/CD24
lo
 (Fig. 7C) for comparison.  
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Figure 4.1 Schematic representation of tumor cell heterogeneity on tumor development and 
therapeutic resistance. (A) Increasing cellular heterogeneity is associated with aggressive, drug-
resistant disease. Cells may exhibit various properties such as therapeutic resistance, genomic 
instability, epigenetic modification, metabolic alteration, self-renewal, and quiescence, which 
promote cell survival during therapy. (B) Tumor-initiating cells are believed to exhibit stem-like 
properties such as self-renewal, quiescent, and generation of diverse cell types from a single cell, 
which contributes to tumor cell heterogeneity and facilitates therapeutic resistance. Tumor-
initiating cells may arise stochastically from any cell within the tumor, suggesting plasticity in 
cell behavior. Alternatively, tumor-initiating cells may represent a distinct population within a 
cellular hierarchy.  Although the mechanisms that generate and maintain tumor-initiating cells 
remain unknown, this cell population represents a major challenge to overcoming drug resistance. 
Adapted from Meacham et. al. and Michor et. al. (211, 287). 
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Figure 4.2 Altering APT1 expression changes β-catenin and Notch gene signatures in MDA-
MB-231 cells. (A to C) Gene set enrichment analysis (GSEA) of a top-scoring β-catenin 
overexpression transcriptional signature in MDA-MB-231 cells when APT1 was knocked down 
and compared against control cells [false discovery rate (FDR) q value, 0.073] (A), a Notch 
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inhibition signature when APT1
WT
 was overexpressed and compared against control cells (FDR q 
value, 0.302) (B), and a mammary stem cell signature when APT1
WT
 was overexpressed and 
compared against shAPT1 cells (FDR q value, 0.0001) (C). (D) Heat map of leading edge genes 
identified in the β-catenin and Notch gene signatures shown in Fig. (A) and (B). Data are grouped 
by APT1 knockdown (kd) cells, APT1
WT
 overexpressing (oe) cells, and control (wt) cells. Genes 
identified in the β-catenin signature are highlighted in green. (E) Heat map of leading-edge genes 
obtained from the mammary stem cell signature shown in (C). Data are grouped by APT1 
knockdown (kd) cells, APT1
WT
-overexpressing (oe) cells, and control (wt) cells. (F and G) Gene 
set enrichment analysis (GSEA) of additional top-scoring Cyclin D1 (FDR q-value= 0.014) (B) or 
Myc (FDR q-value= 0.004) (C) transcriptional signatures in MDA-MB-231 cells when APT1
WT
 
was overexpressed and compared against shAPT1 cells. (H and I) Quantitative RT-PCR (qRT-
PCR) validation of target genes identified from the RNA-seq in shAPT1 (D) cells or APT1
WT
-
overexpressing (E) cells. Average fold change in expression shown by qRT-PCR (blue bars) and 
RNA-seq (red bars). Graphs show average of three independent experiments. 
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Figure 4.3 Asymmetric expression of a Sox2-responsive transcriptional reporter requires 
palmitoylation and CDC42. (A) Images of cytokinetic MDA-MB-231 cells stained to show the 
pGF1-SRR2 GFP reporter (red), acetylated tubulin (green), and nuclei (blue). Arrowheads 
indicate asymmetric localization of pGF1-SRR2. Scale bar, 15 µm. (B to C) Distribution dot plots 
showing the difference in mean fluorescence pixel intensity of the pGF1-SRR2 reporter (B) 
across dividing MDA-MB-231 cells. Cells expressing an empty pGF1-mCMV GFP reporter (C) 
were used as a negative control for the reporters. The distribution of the percentage differences of 
all quantified cells was plotted, and cells with a difference of >20% (dotted line) were scored as 
asymmetric. n = 959 cells scored for the experimental group. Each dot represents a single cell. 
Asterisks indicate statistically significant differences between the indicated groups. (D) 
Quantification of dividing MDA-MB-231 cells showing asymmetric localization of the pGF1-
SRR2 GFP reporter after treatment with PalmB or DMSO control (black bars). Cells expressing 
an empty pGF1-mCMV reporter (gray bars) were used as a negative control for reporter 
expression. (E) Quantification of the number of dividing MDA-MB-231 cells showing 
asymmetric localization of pGF1-SRR2 GFP reporter (black bars) when coexpressed with 
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shAPT1, shCDC42, shAPT1 and shCDC42 [double knockdown (DKD)], or shDHHC20. Cells 
expressing an empty pGF1-mCMV GFP reporter (gray bars) were used as a negative control for 
reporter expression, and cells expressing a scrambled (Scr) shRNA sequence were used as a 
negative control for knockdown conditions. **P < 0.01 and ****P < 0.0001, t test (between 
reporters and pGF1-mCMV, D, E) or ANOVA (H). Error bars indicate SD. 
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Figure 4.4 APT1
WT
 is asymmetrically expressed of in dividing mouse embryonic stem cells. 
Representative immunofluorescence of E14 mouse embryonic stem cells overexpressing 
APT1
WT
-CFP-FLAG stained to show APT1 localization with a GFP antibody that cross-reacts 
with CFP (red), acetylated tubulin (green), and nuclei (blue). Scale bars, 15 μm. 
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Figure 4.5  APT1 is required for in vitro colony formation and self-renewal but is 
dispensable for 2D proliferation. (A) Quantification of the average number of shAPT1-, 
APT1
WT
- or APT1
S119A
-expressing colonies grown from MDA-MB-231 cells in soft agar. Cells 
expressing a scrambled (Scr) shRNA sequence were used as a negative control. (B to D) 
Quantification of the average number of colonies formed from MDA-MB-231 shAPT1 cells (B), 
shCDC42 cells (C), both shAPT1 and shCDC42 (double knockdown, DKD) (D) over three serial 
replatings. Cells expressing a scrambled (Scr) shRNA sequence were used as a negative control 
for knockdown.  (E to G) Proliferation curve of adherent MDA-MB-231 cells grown over 72 
hours with knockdown of shAPT1 (E), shCDC42 (F), or both shAPT1 and shCDC42 (double 
knockdown, DKD) (G). Cells expressing a scrambled (Scr) shRNA sequence were used as a 
negative control for knockdown conditions. Each graph shows means taken from three 
independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001, as measured by t test. Error 
bars indicate SEM.  
 
 
 
 
 
 
112 
 
 
Figure 4.6 APT1 and CDC42 regulate the heterogeneous expression of Notch, Wnt, and 
SRR2 transcriptional reporters in colonies. (A) Quantification of the average number of 
colonies formed from MDA-MB-231 cells expressing shAPT1, shCDC42, both shAPT1 and 
shCDC42, or control cells treated with Wnt inhibitor (IWP2), or Notch inhibitor (GSI) over 3 
serial replatings. Cells expressing a scrambled (Scr) shRNA sequence were used as a negative 
control for knockdown conditions. (B) Representative fluorescence and bright field images of 
colonies expressing pGF1-Notch, pGF1-TCF/LEF1, or pGF1-SRR2 GFP reporters in MDA-MB-
231 colonies derived from control (Scramble), shAPT1-, or shCDC42-expressing cells. Graphs 
show average of three independent experiments. Scale bars, 100μm. *P < 0.05; **P < 0.01; ***P 
< 0.001; ****P < 0.0001 ANOVA (A) or T-test (Scr Plating 3 vs. shAPT1 Plating 3). Error bars 
indicate standard deviation SD. 
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Figure 4.7 Gating scheme for ALDH+ cells on dissociated colonies or adherent cells. Gating 
strategy for flow cytometry analysis to detect Aldehyde dehydrogenase expressing cells (+ 
ALDH) within dissociated colonies or adherent cells from Fig. 7. DEAB-treated cells served as 
negative control (- ALDH) and were used to determine gating for ALDH+ cells. Size of 
population denoted with percentages. Flow cytometry lots are representative of six independent 
experiments. 
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Figure 4.8 APT1 and CDC42 regulate the distribution of cell populations within colonies. 
(A) Pie chart analysis of CD44
+
/CD24
lo
/ALDH
+ 
, CD44
+
/CD24
-
/ALDH
+ 
, 
 
CD44
+
/CD24
lo
/ALDH
- 
, CD44
+
/CD24
-
/ALDH
-  
populations from cells grown in colonies or adherent. Values listed in 
table as percentage. n = 8 independent experiments.  Representative flow cytometry analysis 
showing gating strategy of CD44
+
/ CD24
lo
 cells (red box) in cells dissociated from colonies or 
adherent. The population was gated off of ALDH
+
 cells, as shown in fig. S7. The percentages 
inside the red box indicate the relative proportion of the CD44
+
/CD24
lo 
cell population. Cells 
were stained with phycoerythrin (PE)–conjugated anti-CD24 (CD24-PE) (x axis) and 
allophycocyanin (APC)–conjugated CD44-APC (y axis). Flow cytometry plots are representative 
of results from six independent experiments. 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Summary 
 Numerous recent studies have unearthed novel roles for palmitoylation on various 
cellular processes, especially during development and within tumors. However, the biological 
function of the depalmitoylating enzyme APT1 still remains poorly characterized. I have 
identified a mechanism for palmitoylation that regulates the asymmetric localization of the cell-
fate determinants in dividing cancer cells through interaction with a canonical polarity regulator 
in a potential feedforward manner.  In addition to protein localization, I have also demonstrated 
that palmitoylation promotes the asymmetric expression Wnt, Notch, and Sox2 transcriptional 
reporters between daughter cells.  Suggestive of cell fate regulation, gene set enrichment analysis 
(GSEA) revealed gene signatures correlating with cell identity and Wnt and Notch signaling 
activity when APT1 was silenced or overexpressed. Finally, I have shown a requirement for 
APT1 on the anchorage independent growth, clonal expansion, self-renewal, and cellular 
heterogeneity of triple receptor negative breast cancer cells.  In this dissertation, I have presented 
palmitoylation as a major mechanism of asymmetric cell division that maintains Notch- and Wnt-
associated protein dynamics, gene expression, and cellular functions. 
 In Chapter 2, I utilized an RNAi approach, pharmacologic inhibition, and palmitoylation-
deficient mutants to establish a requirement for palmitoylation on asymmetric Numb and β-
catenin localization. For the first time, I demonstrated that human MDA-MB-231 breast cancer 
cells underwent asymmetric division in vitro under normal growth conditions. By expressing Wnt 
and Notch transcriptional GFP reporters, I demonstrated asymmetric reporter activity was 
established by APT1 and DHHC20. These data together establish a precedent for palmitoylation 
on asymmetric protein localization and downstream Notch and Wnt signaling activity.  
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  In Chapter 3, I employed a cell-imaging based approach to interrogate how 
palmitoylation-mediated protein polarity was established. With fixed immunofluorescence, live-
cell imaging, and modification of the ABE assay, I observed APT1 and bulk palmitoylated 
proteins were asymmetrically localized in dividing cells, and this localization required APT1 
catalytic activity. Furthermore, I observed APT1 and zDHHC20 were spatially segregated to 
membrane regions enriched for lipid rafts and palmitoylated proteins. Together, these data 
suggest protein asymmetry may be reinforced by local palmitoylation cycles at the plasma 
membrane. Utilizing point mutants of constitutively active CDC42, catalytically inactive APT1, 
and CDC42 and APT1 double knockdown, I found APT1 asymmetric localization was reinforced 
by CDC42 activity. Palmitoylated CDC42 was observed to also promote asymmetric APT1 
localization, suggesting it is a substrate of APT1. Similar observations were found for asymmetric 
β-catenin (and, to a lesser extent, Numb) localization. The data presented in Chapter 3 
demonstrate an interdependence of APT1 and CDC42 activity for their own asymmetric 
localization, which may regulate cell polarity in a feedforward manner  
 In Chapter 4, I applied GSEA on RNAseq data generated from APT1 knockdown or 
expression to determine whether palmitoylation affected gene expression in MDA-MB-231 on a 
global scale. I observed gene signatures associated with Wnt and Notch signaling and cell fate 
determination, in addition to a requirement for palmitoylation on asymmetric Sox2 reporter 
expression, a pathway implicated in stem-cell fate. Together, these results suggest a larger role 
for APT1 expression on cell identity. Utilizing the colony formation and replating assays, I 
discovered APT1 was required for the clonogenic growth and self-renewal of MDA-MB-231 
cells. Applying flow cytometry and transcriptional reporter expression, I found the cellular 
heterogeneity of colonies required APT1 (and CDC42). Together, these findings imply a role for 
APT1 specifically, and palmitoylation in general, on the regulation of cell identity and function. 
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 This dissertation provides novel insights into the role of APT1 and palmitoylation on 
cellular processes necessary for cancer and stem cell biology. In this chapter, I will outline two 
key areas for further exploration to explore the role of APT1 on the cell fate determination of 
progenitor cells, and during tumor development.  
 
5.2 Understanding regulation of signaling activity by palmitoylation  
 Many outstanding questions remain, including the identification of palmitoylated 
substrates and how the palmitoyl group affects substrate activity and localization. The 
experiments proposed in this subsection seek to shed light on how palmitoylation affects cell 
identity through signaling activity.  
 β-catenin cortical localization is mediated through association with cadherins at tight 
junctions (237, 238). Having shown palmitoylation of β-catenin and enhanced downstream Wnt 
activity in APT1 knockdown cells, I will examine whether β-catenin palmitoylation maintains its 
stability and nuclear translocation, its cortical association, or both. A screen identified Cys
466
, 
within armadillo repeat domains, may be palmitoylated (245). I have also identified 3 additional 
cytosolic facing and potentially conserved sites (Cys
429
, Cys
439
, and Cys
619
) with CSS-Palm (Fig. 
5.1 A). I hypothesize these four residues promote β-catenin stability to propagate downstream 
Wnt, or promotes cadherin and cytoskeletal interaction. Cys
429 
and Cys
466
 are also located near a 
TCF/Lef binding cleft indicating these two residues may regulate β-catenin nuclear activity (Fig. 
5.1 B). Having generated single and combination point mutants of Cys
429
, Cys
439
, Cys
466
, and 
Cys
619
, I will assess whether mutation of these sites affects palmitoylated β-catenin protein levels, 
and if these sites sterically hinder interaction with the GSK3β-Axin2-APC destruction complex or 
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cadherins. I could also test whether β-catenin palmitoylation is modulated by exogenous Wnt 
stimulation to determine how palmitoylation affects downstream signaling responses. 
 Live-cell analysis of U2OS cells shows β-cateninWT is partitioned to the plasma 
membrane of the daughter cell that emerged from the same side of the mother cell where β-
catenin
WT
 was initially concentrated. APT1
WT
 co-segregated with β-cateninWT, and was retained 
in the daughter cell with high β-catenin signal as indicated by line-scan analysis of YFP and CFP 
pixel intensity along the division axis (Fig. 5.1 C).  Interestingly, β-cateninWT appears to be 
restricted
 
to the plasma membrane while APT1
WT
 was predominantly cytosolic, suggesting 
asymmetric β-catenin localization could be maintained in a negative feedback manner  (Fig. 5.1 
C).  Finally, knocking down APT1 decreased the percentage of cells with asymmetric β-catenin 
(Fig. 5.1 D). Using the palmitoylation-deficient mutants, I would interrogate whether these 
palmitoylation deficient mutants are unable to: 1) asymmetrically localize during cell division, 
and 2) localize to the plasma membrane. Further examination of GSEA signatures reveals a 
negative correlation with protein-membrane trafficking in APT1 knockdown cells, supporting 
conclusions that loss of protein asymmetry was due to disrupted protein transport to the plasma 
membrane (Fig. 5.2 A). High resolution TIRF microscopy could also be employed to investigate 
how palmitoylation affects the membrane turnover of APT1, β-catenin, and also Numb.   
 How palmitoylation regulates transcription is also poorly understood. To determine 
whether Cys
429
, Cys
439
, Cys
466
, and Cys
619
 disrupt Wnt-induced transcriptional activity, I could 
express these point mutants in pGF1-TCF/Lef1 GFP reporter cells to examine if asymmetric 
reporter activity is disrupted and/or suppressed. This strategy will also be employed to examine 
whether the Numb
AAA
 palmitoylation-deficient mutant affects Notch signaling and reporter 
activity.   
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 CDC42 did not significantly affect Numb asymmetric localization or Notch reporter 
expression in daughter cells. As mentioned in Chapter 3, Numb localization may instead require 
the Scribble and Crumbs polarity complexes.  As components of these two complexes are known 
to be palmitoylated, I could examine if Scribble and Crumbs palmitoylation-deficient mutants 
disrupt Numb asymmetric localization and if Numb palmitoylation facilitates interactions with 
these two complexes. This may uncover potential palmitoylation-driven crosstalk between the 
CDC42, Scribble, and Crumbs complexes during the establishment of cell polarity.  
 A recent RNAi and misexpression screen identified wing development defects in D. 
melanogaster when DHHCs were overexpressed (321), providing insights into a role for 
palmitoylation on tissue morphogenesis. Positive correlations with late stem-cell differentiation in 
APT1 knockdown cells and downregulation of a mammary luminal signature in APT1 
overexpressing cells (Fig. 5.2 B) also support a role for APT1 on cell identity. Knocking down 
APT1 was associated with suppressed 3’UTR regulation and ribosome biogenesis, while APT1WT 
overexpression was correlated with chromosome segregation as compared to control cells (Fig. 
5.3 A).  Furthermore, APT1 overexpression or knockdown was strongly correlated with 
progenitor cell identity pathways and epigenetic regulation (Fig. 5.3 B). These preliminary 
findings imply APT1 may have a role on the regulation of gene expression and signaling 
pathways involved in stem cell fate determination and embryonic patterning, which are also 
frequently disrupted in tumors (322–326). Expression of Numb and β-catenin palmitoylation-
deficient mutants in progenitor cells or in embryos would also clarify if palmitoylation is vital for 
embryonic and stem cell development.  
 The experiments presented in this section will provide key insights into the spatio-
temporal regulation of palmitoylation on protein-protein interactions and developmental 
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processes. This will greatly contribute to our understanding of how developmental signaling 
pathways and processes activity may be disrupted in disease progression. 
 
5.3 Determining role of palmitoylation on drug resistance and therapeutic potential for 
APT1 inhibitors 
 Increasing cellular heterogeneity is a key contributor to tumor recurrence, and may arise 
from an accumulation of mutations as a consequence of therapeutic resistance. How distinct 
tumor subpopulations inherit mutations is unclear, but may involve asymmetric cell division. In 
Chapter I, various studies were described demonstrating zDHHC function on tumor progression; 
in contrast, the biological function of APT1 is largely unknown. According to TCGA, APT1 is 
predominantly amplified in human tumors, including invasive breast carcinomas, and may 
correlate with shortened survival.  Here, I will outline a strategy to examine the regulation of 
survival, cellular heterogeneity, and drug resistance of tumor cells by APT1.  
 Cisplatin is a common first-line therapy for breast cancer, but cisplatin-resistance is 
common to triple receptor negative breast cancer and contributes to poor patient prognosis (327, 
328). I hypothesize loss or inhibition of APT1 may increase the sensitivity of MDA-MB-231 cells 
to cisplatin. Preliminary data indicates cisplatin treatment decreases the size and number of APT1 
knockdown colonies as compared to control (Fig. 5.4 A). The findings in Chapter 4 imply APT1 
maintains self-renewing, tumorigenic CD44
+
/ CD24
lo
/ ALDH
+
 cells, which are known to be 
therapy resistant and able to generate cell diversity. Further analysis of cisplatin-treated colonies 
reveals an expected expansion of CD44
+
/ CD24
lo
/ ALDH
+
 cells, representative of drug resistant 
cell, and altered population distribution. Interestingly, an approximately 1.2-fold reduction of the 
CD44
+
/ CD24
lo
/ ALDH
+
 population was observed in treated APT1 knockdown cells as compared 
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to treated control conditions (12.0% vs. 13.9%) (Fig. 5.4 B). Cell death was also increased in 
APT1 knockdown cells treated with cisplatin for 72 hours as compared to control (Fig. 5.4 C). 
While these observations must be validated, these preliminary findings suggest loss of APT1 
increases the sensitivity of MDA-MB-231 cells to cisplatin. Importantly, repeating these 
experiments in control cells treated with PalmB or ML-348 would determine if pharmacologic 
APT1 inhibition: 1) phenocopies APT1 silencing, and 2) sensitizes resistant cells to cisplatin. 
Sorting and replating cisplatin-treated cells would further test if the self-renewal of CD44
+
/ 
CD24
lo
/ ALDH
+
 and population distribution is exhausted by loss of APT1. I could also examine 
APT1 knockdown or pharmacologic inhibition in combination with other common breast cancer 
therapies (e.g. cytoskeletal disruptors, receptor tyrosine kinase inhibitors, radiotherapy, etc. (329, 
330)) to assess alterations in cell survival, heterogeneity, and drug sensitivity. Repeating these 
experiments with patient-derived cells in combination with organoid formation and xenograft 
transplantation would give greater insights into the clinical impact of APT1 inhibition. 
 GSEA indicates APT1 knockdown cells are negatively correlated with DNA repair and 
G2M checkpoint signatures as compared to control cells, and APT1 overexpression correlates 
with chromosome segregation (Fig. 5.2 A, 5.5 A). These signatures suggest perturbations to 
APT1 disrupt genome stability and cell cycle progression.  Segregating DNA and damaged 
organelles to one daughter cell has been proposed as a potential mechanism of ensuring stem cell 
fitness and survival (205, 317, 331–333). It is entirely possible this partitioning may be employed 
by tumor cells to promote the unequal inheritance of mutations, while eliminating cells fated for 
apoptosis in order to promote tumor growth and metastasis. A preliminary observation of control 
MDA-MB-231 cells shows asymmetric expression of the DNA repair enzymes 53BP1 and 
BRCA1 in daughter nuclei (Fig. 5.5 B). This result implies that the DNA repair machinery is 
recruited to the cell with greater damage, or DNA repair is suppressed in one daughter cell upon 
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recruitment. I could examine the expression of 53BP1, BRCA1, Chk1, and γ-H2AX to determine 
if APT1 knockdown or pharmacologic inhibition increases DNA damage. To address the 
mechanism of asymmetric DNA repair, I could initiate DNA damage (drug- or radio-induced) 
and examine γ-H2AX focus formation over time to: 1) ascertain unequal foci distribution 
between daughter cells, 2) at what point in the DNA damage response is asymmetry first 
observed, and 3) if APT1 knockdown or pharmacologic inhibition increases symmetric 
accumulation of damage.  
 Cell death is a fate decision and may be asymmetrically induced in one daughter cell 
(334). Glioma initiating cells have been reported to undergo asymmetric division and apoptosis as 
well (335). I find APT1 knockdown cells positively correlate with an apoptotic execution gene 
signature, which may promote the observed increase in cisplatin-induced cell death (Fig. 5.5 C).  
As mentioned in Chapter I, several apoptotic regulators are palmitoylated, and thus, may be 
asymmetrically partitioned or induced. Preliminary quantification of cleaved caspase-3 
fluorescence intensity in non-mitotic MDA-MB-231 cells indicates increased expression in APT1 
knockdown cells (Fig. 5.5 D, E). Cleaved caspase-3 is moderately increased in DHHC20 
knockdown cells, implying greater specificity for apoptotic regulators not seen with APT1. I 
would assess asymmetric expression of cleaved caspase-3, BAX, and Fas death receptor between 
daughter cells, and determine whether cisplatin, APT1 inhibition, and combination treatment 
modulates asymmetric apoptosis.  Additionally, staining isolated CD
44
/ CD24
lo
/ ALDH
+ 
would 
also clarify whether APT1 knockdown or pharmacologic inhibition increases cell death, which 
would contribute to a decreased tumorigenic population. These experiments would assess if 
accumulating DNA damage promote cell death induced by silencing APT1.  
  Asymmetric organelle segregation may also be a way to induce unequal protein 
translation. As shown in Fig. 5.2 A, APT1 knockdown negatively correlates with ribosome 
 
 
123 
biogenesis and 3’UTR translational regulation. Asymmetric induction of histone modifications 
have been observed in germline stem cells (336), and it is possible this process may occur in 
tumor cells to differentially regulate gene expression between daughter cells. GSEA shown in 
Fig. 5.2 B suggests epigenetic regulation may be altered by APT1 overexpression or knockdown. 
I could assess cells for asymmetric expression of HDACs, HATs, and HMTs in control cells, and 
determine if asymmetry is disrupted with APT1 inhibition.  The experiments to this point would 
provide insights into whether favorable mutations are unequally inherited, with implications for 
the development of disease recurrence. 
 Ultimately, I could examine how protein palmitoylation affects signaling pathways 
necessary for tumor initiation and growth.  Expression of Numb and β-catenin palmitoylation 
deficient mutants would determine if loss of palmitoylation inhibits or exacerbates colony 
formation and self-renewal. I could also examine transcriptional Wnt and Notch reporter 
expression to better understand if signaling activity is altered and if expression is symmetric 
within colonies with these mutants. These experiments could be extended to other palmitoylated 
substrates such as EGFR and Ras. Single RNAseq of dissociated colonies expressing Numb and 
β-catenin palmitoylation deficient mutants could potentially identify novel biomarkers that could 
be targeted therapeutically.  
 The experiment in this section can be applied to various cancer including blood, ovarian, 
glioblastoma, and lung to better understand the requirement for APT1 on tumor progression. 
Together, the proposed experiments would contribute to our understanding of how tumor 
heterogeneity is established through asymmetric cell division, and may uncover a role for 
palmitoylation inhibitors in the clinic. 
 
 
 
124 
5.4 Conclusions  
 This work presents a conceptual framework for palmitoylation-mediated asymmetric cell 
division, with implications for tumor cell heterogeneity and stem cell homeostasis. The future 
experiments proposed in this chapter will build on this work to provide greater understanding into 
the spatio-temporal regulation of proteins at the plasma membrane, and into the regulation of 
signaling activity and gene expression during development and disease. 
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Figure 5.1 Role of palmitoylation on asymmetric β-catenin localization. (A) Sequence 
comparison of β-catenin armadillo repeats from fruit fly (Drosophila melanogaster), zebrafish 
(Danio rerio), mouse (Mus musculus), and human (Homo sapiens). Putative palmitoylated 
cysteines are highlighted in green. (B) Crystal structure of the D. melanogaster β-catenin 
armadillo repeats indicating putative palmitoylated residues C429, C439, C466 and C619 in 
yellow. (C) Time-lapse images of dividing U2 OS cells coexpressing β-cateninWT -YFP (yellow), 
APT1
WT
-CFP (blue), and mCherry–Histone H2B (red). Fluorescence pixel intensity was 
measured along the division axis (dashed line), and the corresponding pixel values of β-catenin 
(yellow line) and APT1 (blue line) along the division axis were plotted on graphs. Red 
arrowheads on images and graphs indicate the peak β-catenin and APT1 pixel intensity at the 
membrane or cytokinetic midbody. Time is shown in minutes (min). a.u., arbitrary units. Scale 
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bar, 15 µm. (E) Quantification of the number of dividing U2 OS cells showing asymmetric 
localization of β-cateninWT-YFP in control or shAPT1 cells treated with CHAPS (black bar) or 
Wnt3a (gray bar). Cells expressing a scrambled (Scr) shRNA sequence were used as a negative 
control for APT1 knockdown.  *P < 0.05, t test and ANOVA. Error bars indicate SD. 
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Figure 5.2 GSEA signatures correlating with protein trafficking and cell identity in  
APT1 knockdown or APT1
WT
 overexpressing cells. (A and B) Gene set enrichment analysis 
(GSEA) of a top-scoring protein localization to the endoplasmic reticulum, [false discovery rate 
(FDR) q value, <0.0001], localization to organelles [FDR q-value= 0.03], and targeting to 
membrane when APT1 was knocked down and compared against control cells [FDR q-value= 
0.009] (A). Gene set enrichment analysis (GSEA) of additional top-scoring late embryonic cell 
differentiation (FDR q-value <0.0001) or genes downregulated in mature mammary luminal cells 
(FDR q-value= 0.007) (B). 
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Figure 5.3 GSEA signatures correlating with protein translation, cell identity, and 
epigenetic modification protein trafficking and cell identity in APT1 knockdown or APT1
WT
 
overexpressing cells. (A and B) Gene set enrichment analysis (GSEA) of a top-scoring 3’UTR 
mediated translation [false discovery rate (FDR) q value, <0.0001] and ribosome biogenesis 
[FDR q-value= 0.0002] signatures when APT1 was knocked down and compared against control 
cells.  Top-scoring chromosome segregation [FDR q-value= 0.05] signature when APT
WT
 was 
overexpressed and compared against control cells (A). Gene set enrichment analysis (GSEA) of 
top-scoring T lymphocyte progenitor (FDR q-value <0.0001), TGF- β signaling [FDR q-value= 
0.354], and downregulation of target genes upon HDAC1 or HDAC1 pharmacologic inhibition 
[FDR q-value <0.0001] when APT1 was knocked down and compared against control cells.  Top-
scoring EZH2 target gene expression [FDR q-value= 0.007] signature when APT
WT
 was 
overexpressed and compared against control cells (B). 
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Figure 5.4 APT1 knockdown may increase sensitivity of cisplatin-resistant MDA-MB-231 
cells to drug treatment. A) Preliminary quantification of the average number of colonies grown 
in 10m cisplatin or vehicle from MDA-MB-231 shAPT1 cells. Cells expressing a scrambled 
(Scr) shRNA sequence were used as a negative control. n = 3 independent experiments.  (B) Pie 
chart analysis of CD44
+
/CD24
lo
/ALDH
+ 
, CD44
+
/CD24
-
/ALDH
+ 
, 
 
CD44
+
/CD24
lo
/ALDH
- 
, 
CD44
+
/CD24
-
/ALDH
-  
populations from colonies isolated in (A). Values listed in table as 
percentage. n = 3 independent experiments.  (C) Proliferation curve of adherent shAPT1 MDA-
MB-231 cells grown over 72 hours and treated with 10m cisplatin or vehicle.  Cells expressing a 
scrambled (Scr) shRNA sequence were used as a negative control for knockdown conditions. 
Each graph shows means taken from three independent experiments. **P < 0.01, ***P < 0.001, 
and ****P < 0.0001, as measured by t test (vehicle vs cisplatin) or ANOVA. Error bars indicate 
SEM.  
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Figure 5.5 DNA damage repair and apoptosis may be dependent on APT1. (A) Gene set 
enrichment analysis (GSEA) of a top-scoring DNA repair [false discovery rate (FDR) q value, 
0.094] and G2M checkpoint [FDR q-value= 0.147] signatures when APT1 was knocked down 
and compared against control cells. (B) Representative immunofluorescence of cytokinetic MDA-
MB-231 control cells stained to show asymmetric or symmetric 53BP1 or BRCA1 (red), 
acetylated tubulin (green), and nuclei (blue). Scale bars, 15 μm. (C) Gene set enrichment analysis 
(GSEA) of a top-scoring apoptotic [FDR q-value= 0.398] signature when APT1 was knocked 
down and compared against control cells. (D) Representative immunofluorescence of non-
dividing MDA-MB-231 shAPT1 or scrambled (Scr) control cells stained for cleaved caspase 3 
(red), acetylated tubulin (green), and nuclei (blue). Scale bars, 30 μm.   (E) Distribution dot plots 
showing mean fluorescence pixel intensity of cleaved caspase 3 signal of MDA-MB-231 shAPT1 
(D) and shDHHC20 cells. Cells expressing a scrambled (Scr) shRNA sequence were used as a 
negative control for knockdown conditions. n = 127 cells scored for the experimental group from 
1 experiment. Each dot represents a single cell 
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